<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Medical Oncology via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Medical Oncology' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Medical+Oncology&t=Medical+Oncology&s=Search&f=source]]></link>
        <lastBuildDate>Sun, 21 Mar 2010 13:52:54 +0100</lastBuildDate>
        <item>
            <title>Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells</title>
            <link>http://www.medworm.com/index.php?rid=3386314&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1523q4v634645825%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Indoleamine 2,3-dioxygenase (IDO), a catabolizing enzyme of tryptophan, is a novel immunosuppressive agent blocking T-cell
 activation in neoplastic cells, including acute myeloid leukemia (AML) cells. IDO inhibitors as 1-methyl tryptophan (1MT)
 can abrogate IDO enzymatic activity and may result in an effective immune response. Mononuclear cells (MNCs) were separated
 from peripheral blood of 25 AML patients and 25 normal adults. IDO expression was detected by RT-PCR and its enzymatic activity
 by a colorimetric method. MNCs were cultured and the effects of Adriamycin, 1MT and a mixture of both on blast and lymphocyte
 cell counts after 24 and 72&amp;nbsp;h were detected. IDO mRNA and activity were detected in 52% of patients and absent in normal subjects.
 There was a sig...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386314</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:34 +0100</pubDate>
            <guid isPermaLink="false">3386314</guid>        </item>
        <item>
            <title>Clinical significance of the ratio between the alpha 2 plasmin inhibitor–plasmin complex and the thrombin–antithrombin complex in advanced non-small cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3386315&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg4741737138n5337%2F</link>
            <description>In this study, a low PIC/TAT ratio and poor PS were significant independent negative prognostic factors for
 survival in patients with advanced NSCLC. The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants
 in the future.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9454-yAuthors
		Katsuhiro Masago, Kyoto University Department of Respiratory Medicine, Graduate School of Medicine 54 Syogoin-Kawaracho, Sakyo-Ku Kyoto 606-8507 JapanShiro Fujita, Institute of Biomedical Research and Innovation Division of Integrated Oncology Kobe JapanTadashi Mio, Kyoto University Department of Respiratory Medicine, Graduate School of Medicine 54 Syogoin-Kawaracho, Sakyo-Ku Kyoto 606-8507 JapanYosuke Togashi, Kyoto University Department of Respirator...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386315</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:33 +0100</pubDate>
            <guid isPermaLink="false">3386315</guid>        </item>
        <item>
            <title>ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients</title>
            <link>http://www.medworm.com/index.php?rid=3386316&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0868425164582775%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The ADAMs is a multi-functional gene family of membrane proteins possessing a disintegrin and metalloprotease domain. They
 have potential implications for the metastasis of human tumor cells via cell adhesion and protease activities. However, no
 studies have yet comprehensively examined the expression of ADAMs in gallbladder carcinoma. The aim of this study was to test
 the hypothesis that ADAM-17 (otherwise known as tumor necrosis factor-α converting enzyme) is involved in the progression
 of gallbladder carcinoma. Two hundreds samples of gallbladder carcinoma and sixty non-cancerous gallbladder samples were used
 to measure the expression of total ADAM-17 by enzyme-linked immunosorbent assay, and the precursor and active forms by western
 blotting analysis. Express...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386316</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:32 +0100</pubDate>
            <guid isPermaLink="false">3386316</guid>        </item>
        <item>
            <title>Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=3386318&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F767qr426x4n2w73m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Astrocyte-elevated gene-1 (AEG-1) plays an important role in diverse cancers and its up-regulation is associated with poor
 survival of patients. However, the status of AEG-1 expression and its significance in gastric cancer are still unclear. In
 this study, the expression of AEG-1 was studied in different gastric cancer cell lines and gastric cancer tissues. Expression
 of AEG-1 was significantly higher in gastric cancer tissues than that in normal tissues. Overexpression of AEG-1 was found
 in 62.9% of gastric cancers and significantly associated with TNM stage and Ki-67 proliferation index (P&amp;nbsp;&amp;lt;&amp;nbsp;0.01). For survival study, overexpression of AEG-1 was significantly associated with poor survival (P&amp;nbsp;&amp;lt;&amp;nbsp;0.01). Further multivariate analysis suggest...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386318</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:31 +0100</pubDate>
            <guid isPermaLink="false">3386318</guid>        </item>
        <item>
            <title>Painless acute pancreatitis associated with sorafenib treatment: a case report</title>
            <link>http://www.medworm.com/index.php?rid=3386317&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff356xt0nh4gg8332%2F</link>
            <description>We report the case
 of a patient with painless acute pancreatitis associated with sorafenib treatment. The patient was a 71-year-old man who had
 undergone surgery for left renal carcinoma and tumor thrombus in the inferior vena cava and right atrium (IVC-RA). After a
 follow-up period of 3&amp;nbsp;years, he developed right adrenal metastasis and received interferon (IFN)-alpha treatment. One year
 later, progression of the adrenal metastasis was observed, and he was admitted to a hospital for treatment with sorafenib,
 which was administered at a dose of 800&amp;nbsp;mg/day. Two weeks later, he developed painless acute pancreatitis associated with
 sorafenib treatment. Thereafter, sorafenib treatment was discontinued, and he was treated with conservative therapy. Three
 weeks later, he was disch...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386317</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:31 +0100</pubDate>
            <guid isPermaLink="false">3386317</guid>        </item>
        <item>
            <title>Growth inhibitory effects of DJ-1-small interfering RNA on laryngeal carcinoma Hep-2 cells</title>
            <link>http://www.medworm.com/index.php?rid=3386319&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn242u5u1357w8126%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cancer of the larynx is the commonest head and neck squamous cell carcinoma. The DJ-1 gene is a novel mitogen-dependent oncogene.
 Survivin is a structurally unique member of the inhibitors of apoptosis proteins. DJ-1 and survivin play important roles in
 carcinogenesis. The function of DJ-1, and the relationship between DJ-1 and survivin in laryngeal carcinoma, has never been
 explored. Small interfering RNAs (siRNAs) directed against the DJ-1 gene were initially transfected into laryngeal carcinoma
 Hep-2 cells with liposome. The viability of Hep-2 cells was then detected by the MTT assay. The changes in cell-cycle distribution
 were monitored by flow cytometry. Finally, changes in DJ-1 and survivin genes mRNA and protein levels were evaluated by semi-quantitative
 RT...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386319</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:30 +0100</pubDate>
            <guid isPermaLink="false">3386319</guid>        </item>
        <item>
            <title>β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells</title>
            <link>http://www.medworm.com/index.php?rid=3386321&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fmrh465147v4435m2%2F</link>
            <description>In this study, the expression of β-catenin in astrocytic glioma tissues with
 different grade and human normal cerebral tissues was examined using reverse transcription-polymerase chain reaction (RT-PCR)
 and immunohistochemistry. We found a higher expression level of β-catenin in astrocytic glioma patients with high grade in
 comparison with the normal controls. Additionally, siRNA was transfected into human U251 glioblastoma cells by liposome after
 the design of siRNA was confirmed to effectively inhibit the expression of β-catenin by RT-PCR. Compared to the control siRNA
 group, siRNA-mediated knockdown of β-catenin in human U251 cells inhibited cell proliferation, resulted in cell apoptosis,
 and arrested cell cycle in G
 0/G
 1. Additionally, downregulation of β-catenin decrease...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386321</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:28 +0100</pubDate>
            <guid isPermaLink="false">3386321</guid>        </item>
        <item>
            <title>The invasive malignancy from peritoneal epithelial cell: a report of four cases and review of literature</title>
            <link>http://www.medworm.com/index.php?rid=3386320&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw866247261103758%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To analyze the clinical characteristics, diagnosis and treatment of primary peritoneal carcinoma (PPC) and to review the literature,
 so as to raise the awareness of the disease. Four cases of PPC diagnosed in our department from March 2005 to September 2007
 were retrospectively analyzed. Four cases were all treated with platinum-based chemotherapy. They were treated with intraperitoneal
 chemohyperthermia (IPCH) with cisplatin, carboplatin or oxaliplatin with a closed sterile circuit of 1,000&amp;nbsp;ml physiologic
 saline and inflow temperature is 43°C, while they were receiving high-intensity focused microwave hyperthermia (HIFMH) concomitantly.
 Intravenous paclitaxel or docetaxel was used in three patients, while cyclophosphamide and adriamycin injection in another
...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386320</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:28 +0100</pubDate>
            <guid isPermaLink="false">3386320</guid>        </item>
        <item>
            <title>Gemcitabine and cisplatin in patients with carcinoma of unknown primary site</title>
            <link>http://www.medworm.com/index.php?rid=3386323&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl8n7vh772gk58500%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The optimal therapy for carcinoma of unknown primary site (CUPS) is still under investigation. In this retrospective trial,
 we reported the response rates and overall and progression free survival of 23 CUPS patients that were treated with gemcitabine
 and cisplatin. The mean age of the patients was 54.95 (32–77). Sixteen (69.6%) of them were males and 7(30.4%) females. Totally
 109 cycles with a mean of 6 were administered. Thirteen of 23 patients (56.5%) presented with only one metastatic site, and
 the liver is the most frequent metastatic site (39.1%). Histologic types were adenocarcinoma in 14 patients (60.8%), squamous
 carcinoma in 1 patient (4.8%), epithelioid cancer in 3 patients (13%) and undifferentiated cancer in 5 patients (21.7%). Three
 patient achieve...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386323</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:27 +0100</pubDate>
            <guid isPermaLink="false">3386323</guid>        </item>
        <item>
            <title>The protective effects of intratympanic dexamethasone and vitamin E on cisplatin-induced ototoxicity are demonstrated in rats</title>
            <link>http://www.medworm.com/index.php?rid=3386322&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv887074425566h03%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cisplatin ototoxicity is a major dose-limiting factor in the treatment of several neoplasms. Dexamethasone and vitamin E are
 two slow-acting free radical cleaners, and they have been shown to ameliorate nephrotoxicity and endothelial cell damage in
 animals receiving cisplatin. The purpose of the study was to determine the effectiveness of vitamin E and dexamethasone as
 an otoprotectant intratympanically. Prospective, randomized controlled trial in the rat model. Wistar rats were sedated using
 50&amp;nbsp;mg/kg intraperitoneal ketamine and 7.5&amp;nbsp;mg/kg xylazine. Baseline auditory brainstem response (ABR) testing was performed
 in response to clicks and 4.8-, 12-, 16-kHz tone bursts. After auditory thresholds were determined, the animals received intraperitoneal
 drug a...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386322</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:27 +0100</pubDate>
            <guid isPermaLink="false">3386322</guid>        </item>
        <item>
            <title>Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=3386325&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk6454u7vj73jq001%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Runx3 and CHFR genes were defined as tumor suppressor genes in gastric cancer (GC) recently. This paper was to investigate
 the roles of methylation and expression status of Runx3 and CHFR genes in GC patients. Methylation-specific polymerase chain
 reaction (MSP) and bisulfite DNA sequencing (BSP) were used to detect methylation status of Runx3 and CHFR genes in GC patients.
 The expression of Runx3 and CHFR in GC patients was analyzed by reverse transcription polymerase chain reaction (RT–PCR) and
 immunohistochemical analysis. The expression of the protein and mRNA decreased remarkably in the patients with aberrant promoter
 methylation of Runx3 and CHFR genes. The methylation status of Runx3 and CHFR were inversely related to the tumor size, tumor
 invasion depth ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386325</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:25 +0100</pubDate>
            <guid isPermaLink="false">3386325</guid>        </item>
        <item>
            <title>Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549</title>
            <link>http://www.medworm.com/index.php?rid=3386324&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fut002r42r61v4127%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Rho and Rho-associated kinase play an important role in focal adhesion, stress fiber formation and cell motility. Fasudil
 is a kind of Rho kinase inhibitor. The effect and precise molecular mechanism of fasudil on the biology behavior of lung cancer
 cell A549 remains unclear. The cytotoxic effect of fasudil on A549 cell was measured by 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
 bromide (MTT) assay. Wound-healing assay was used to evaluate the effect of fasudil on migration activity of A549 cells. The
 invasion activity of A549 cells was detected by transwell chamber assay. The expression of MMPs was measured by gelatin zymography.
 RT-PCR and western blot were used to investigate the molecular change of A549 cells after treated with fasudil. Fasudil-inhibi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386324</comments>
            <pubDate>Fri, 19 Mar 2010 06:52:25 +0100</pubDate>
            <guid isPermaLink="false">3386324</guid>        </item>
        <item>
            <title>Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation</title>
            <link>http://www.medworm.com/index.php?rid=3380052&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl071774j361wx47r%2F</link>
            <description>In this study, PTEN promoter status and its correlation with genetic and pathologic parameters were analyzed in genomic DNA from Iranian patients
 with breast cancer. DNA methylation patterns in the CpG islands were determined by a methylation-specific PCR (MSP) assay.
 PTEN promoter methylation was found to be present in 37 of 53(70%) tumor tissues and none in 20 normal counterparts. Moreover,
 promoter methylation was found in patients with heterozygote mutation in the PTEN gene. The pathological history of cancerous tissue sections showed that PTEN gene could be inactivated at the stages III and IV in sporadic breast cancer. These findings suggested that promoter hypermethylation
 of PTEN might contribute to the progression of sporadic breast cancer in human.
 
 
	Content Type Journal A...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3380052</comments>
            <pubDate>Wed, 17 Mar 2010 15:51:54 +0100</pubDate>
            <guid isPermaLink="false">3380052</guid>        </item>
        <item>
            <title>Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3380051&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl5k65j7527n2h4m4%2F</link>
            <description>This study was designed to evaluate the expression of C-erbB-2 and p16 in lung cancers using tissue microarray technology
 and to determine their clinical and pathological significance. Immunohistochemical C-erbB-2 and p16 expressions and their
 associations with clinical and pathological features were analyzed in two tissue microarrays. The membranous and cytoplasmic
 expression rates of C-erbB-2 were 40.5 and 66.5% in non-small cell lung cancers (NSCLCs), and 0 and 9.5% in small cell lung
 cancers (SCLCs), respectively. The nuclear and cytoplasmic expression rates of p16 were 11.5 and 32.2% in NSCLs, and 45 and
 80% in SCLCs, respectively. The cytoplasmic expression of both C-erbB-2 and p16 was more frequent than the membranous expression
 of C-erbB-2 and the nuclear expression of p16. T...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3380051</comments>
            <pubDate>Wed, 17 Mar 2010 15:51:54 +0100</pubDate>
            <guid isPermaLink="false">3380051</guid>        </item>
        <item>
            <title>BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3380053&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl444h531j3u34130%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We sought to improve the understanding of oncogene-dependent and independent non-small-cell lung cancer (NSCLC), which could
 provide insight into mechanism of sensitivity and/or resistance to tyrosine kinase inhibitors or chemotherapeutics. NSCLC
 cell lines with different EGFR genotypes were used in this study; MTT assay and flow cytometry were applied to study the sensitivities
 of these cell lines to gefitinib and cisplatin. Western blot was performed to determine the expression levels of BIM and other
 Bcl-2 family proteins pre- and pro-treatment. Gefitinib provoked apoptosis of caspase activation via the intrinsic pathways
 and significantly up-regulated expression of BIM protein in drug-sensitive PC-9 cell line, but not resistant PC-9/BB4 cell
 line. The knockdow...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3380053</comments>
            <pubDate>Wed, 17 Mar 2010 15:51:53 +0100</pubDate>
            <guid isPermaLink="false">3380053</guid>        </item>
        <item>
            <title>Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia</title>
            <link>http://www.medworm.com/index.php?rid=3380054&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu3967j2475769178%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This prospective, single-arm study utilized alemtuzumab as a single agent in a novel maintenance schedule in previously treated
 chronic lymphocytic leukemia patients with the goal of delaying progression of disease and requirement for chemotherapy. In
 previously treated CLL patients who had achieved stable disease or better, the following schedule of subcutaneous alemtuzumab
 was administered: a dose escalation in the first week (3, 10 and 30&amp;nbsp;mg), followed by 7&amp;nbsp;weeks of 30&amp;nbsp;mg alemtuzumab once weekly,
 16&amp;nbsp;weeks of 30&amp;nbsp;mg once every 2&amp;nbsp;weeks, followed by once every 3&amp;nbsp;weeks for 24&amp;nbsp;weeks. Thus, the entire duration of the planned
 treatment was 48&amp;nbsp;weeks. A total of 12 patients were enrolled 11 of which had at least one marker of p...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3380054</comments>
            <pubDate>Wed, 17 Mar 2010 15:51:51 +0100</pubDate>
            <guid isPermaLink="false">3380054</guid>        </item>
        <item>
            <title>Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=3360386&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F31618r5622v16g11%2F</link>
            <description>In this study, we used an adenovirus(Ad)-mediated transfer of siRNA against bFGF mRNA (Ad-bFGF-siRNA)
 to study the effect of down-regulating bFGF expression on the sensitivity of glioma cells to chemotherapeutics. An optimal
 siRNA sequence specific for bFGF mRNA was cloned into an adenoviral vector and transfected into three glioma cell lines: U251,
 A172, and LN229. Methyl thiazolyl tetrazolium (MTT) assays were used to examine changes in cell proliferation, and changes
 in bFGF mRNA and protein levels in U251 cells were detected using quantitative RT-PCR and Western blot, respectively. Apoptosis
 of U251 cells was detected using Hoechst staining and flow cytometry, with expression of apoptosis-related proteins evaluated
 by Western blot. Following the transfection of a bFGF-specific si...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360386</comments>
            <pubDate>Thu, 11 Mar 2010 02:49:32 +0100</pubDate>
            <guid isPermaLink="false">3360386</guid>        </item>
        <item>
            <title>Nasal septum perforation and bevacizumab</title>
            <link>http://www.medworm.com/index.php?rid=3355672&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd5m70715hl604gv2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The use of targeted/biologic therapies is now commonplace in the treatment of malignant and non-malignant diseases. The novel
 mode of action of these drugs has resulted in unpredictable and in some cases unexpected side effects. Given the widespread
 use of bevacizumab and its distinct mode of action, it is important that oncologists report any unexpected adverse events
 that may be associated with the drug. Herein, we report three cases of spontaneous nasal septum perforation secondary to bevacizumab.
 We hypothesize an etiology for this rare event and reasons why it is reasonable to rechallenge the patient.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9464-9Authors
		Derek G. Power, Memorial Sloan Kettering Cancer Center Department o...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355672</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:59 +0100</pubDate>
            <guid isPermaLink="false">3355672</guid>        </item>
        <item>
            <title>Metastin is not involved in metastatic potential of non-small cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3355673&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F53336175623085t4%2F</link>
            <description>This study shows a lack of direct involvement of metastin in the
 diagnosis and metastatic potential of NSCLC.
 
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s12032-010-9466-7Authors
		Eleni M. Karapanagiotou, Athens School of Medicine, Sotiria General Hospital Oncology Unit, Third Department of Medicine Building Z, Mesogion 152 Athens 115 27 GreeceKalliopi D. Dilana, Athens School of Medicine, Sotiria General Hospital Oncology Unit, Third Department of Medicine Building Z, Mesogion 152 Athens 115 27 GreeceIoannis Gkiozos, Athens School of Medicine, Sotiria General Hospital Oncology Unit, Third Department of Medicine Building Z, Mesogion 152 Athens 115 27 GreeceIoannis Gratsias, Athens School of Medicine, Sotiria General Hospital Oncology Unit, Third Department of Medi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355673</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:58 +0100</pubDate>
            <guid isPermaLink="false">3355673</guid>        </item>
        <item>
            <title>Advances in treatment for relapses and refractory multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3355675&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F471u65n70562j8nt%2F</link>
            <description>This article will review the
 current role for thalidomide, lenalidomide, and bortezomib-based combinations, as well as some preliminary findings for promising
 investigational agents currently in clinical trials for patients with relapsed and/or refractory disease.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9407-5Authors
		Tiffany Richards, MD Anderson Cancer Center Houston TX USADonna Weber, MD Anderson Cancer Center Houston TX USA
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355675</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:56 +0100</pubDate>
            <guid isPermaLink="false">3355675</guid>        </item>
        <item>
            <title>Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study</title>
            <link>http://www.medworm.com/index.php?rid=3355674&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc75203j620741780%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study is to conduct a comparison study between the efficacy and safety of zoledronic acid and clodronate in
 malignant hypercalcemia secondary to bone metastases in Egyptian adult patients. This is a prospective observational study
 conducted 80 patients (40 in each group), who were assigned to receive either zoledronic acid (4&amp;nbsp;mg over a 30&amp;nbsp;min infusion)
 every 3–4&amp;nbsp;weeks or clodronate (a single dose of 1,500&amp;nbsp;mg over a 4&amp;nbsp;h infusion) monthly for 3&amp;nbsp;months. The primary efficacy analysis
 was the proportion of patients with at least one skeletal-related event. The safety was assessed based on the frequencies
 of the reported adverse effects as nausea, vomiting, anemia, etc. The calcium level significantly decreased in both grou...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355674</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:56 +0100</pubDate>
            <guid isPermaLink="false">3355674</guid>        </item>
        <item>
            <title>Recurrent differentiation syndrome or septic shock? Unresolved dilemma in a patient with acute promyelocytic leukemia</title>
            <link>http://www.medworm.com/index.php?rid=3355676&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk7r8827128491w91%2F</link>
            <description>We report an APL patient treated with the AIDA regimen, who experienced both early
 and late DS, a situation where differential diagnosis was difficult.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9462-yAuthors
		Ramzi Jeddi, Aziza Othmana University Hospital Hematology Department Tunis TunisiaHela Ghédira, Aziza Othmana University Hospital Hematology Department Tunis TunisiaRamzi Ben Amor, Aziza Othmana University Hospital Hematology Department Tunis TunisiaSamia Menif, Institut Pasteur Tunis TunisiaZaher Belhadjali, Aziza Othmana University Hospital Hematology Department Tunis TunisiaBalkis Meddeb, Aziza Othmana University Hospital Hematology Department Tunis Tunisia
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355676</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:55 +0100</pubDate>
            <guid isPermaLink="false">3355676</guid>        </item>
        <item>
            <title>Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib</title>
            <link>http://www.medworm.com/index.php?rid=3355677&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa3j3302kk48111kx%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A clinical prognostic model derived from BR.21 trial was established by Florescu et al., which helped to identify a small
 group of patients with non-small cell lung cancer (NSCLC) who might be less likely to benefit from erlotinib therapy. Whether
 the prognostic model derived from Caucasian patients treated with erlotinib will be applied to Asian patients treated with
 gefitinib is still an open question. We reviewed a multi-center clinical trial of Chinese patients with NSCLC treated with
 gefitinib. The data were collected and analyzed according to the prognostic model reported by Florescu et al. One hundred
 and nineteen patients were included in the validation study. Twenty-eight patients, 61 patients, 27 patients, and 3 patients
 were classified into the Low Risk...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355677</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:54 +0100</pubDate>
            <guid isPermaLink="false">3355677</guid>        </item>
        <item>
            <title>Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia</title>
            <link>http://www.medworm.com/index.php?rid=3355678&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2886m750268152g4%2F</link>
            <description>In conclusion, determination of 1236T, C3435T, and G2677T MDR1 polymorphisms might be useful in response prediction
 to therapy with imatinib in patients with CML.
 
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s12032-010-9456-9Authors
		Ling-Na Ni, Nanjing Medical University Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital 300 Guangzhou Rd 210029 Nanjing ChinaJian-Yong Li, Nanjing Medical University Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital 300 Guangzhou Rd 210029 Nanjing ChinaKou-Rong Miao, Nanjing Medical University Department of Hematology, Jiangsu Province Hospital, The First Affiliated Nanjing Medical University Hospital 300 Guangzhou R...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3355678</comments>
            <pubDate>Wed, 10 Mar 2010 16:02:53 +0100</pubDate>
            <guid isPermaLink="false">3355678</guid>        </item>
        <item>
            <title>Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3336463&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F260513201524110n%2F</link>
            <description>This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated,
 extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received
 irinotecan (60&amp;nbsp;mg/m2 on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4&amp;nbsp;weeks. Treatment was repeated until disease progression,
 unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response
 rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival
 (OS) were 5.6 and 8.7&amp;nbsp;months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3–4 neutropenia
 occur...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3336463</comments>
            <pubDate>Wed, 03 Mar 2010 08:07:29 +0100</pubDate>
            <guid isPermaLink="false">3336463</guid>        </item>
        <item>
            <title>Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate</title>
            <link>http://www.medworm.com/index.php?rid=3328335&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F62k0h72t77p10v84%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;There are many controversies regarding the treatment of very early-stage (pT1a/bN0M0) breast cancer (BC), generally considered
 to have a very good prognosis. The debate is the benefit of an adjuvant treatment of HER2-neu (namely HER-2)-positive subcentimetric carcinoma with trastuzumab. Current guidelines do not suggest, with the highest level
 of evidence, whether trastuzumab should be administered after adjuvant chemotherapy in the treatment of high-risk pT1a/bN0M0
 breast cancer. The major phase III trials that confirmed the benefit of adjuvant immunotherapy did not include small (&amp;lt;1&amp;nbsp;cm
 diameter) node-negative breast cancer. Several retrospective case series of HER-2-positive pT1a/bN0M0 carcinoma seem to demonstrate
 that they have a higher risk of relapse ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3328335</comments>
            <pubDate>Tue, 02 Mar 2010 10:07:46 +0100</pubDate>
            <guid isPermaLink="false">3328335</guid>        </item>
        <item>
            <title>Relevance of serum estradiol and estrogen receptor beta expression from a high-incidence area for esophageal squamous cell carcinoma in China</title>
            <link>http://www.medworm.com/index.php?rid=3328334&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn47l0727755jv323%2F</link>
            <description>This study indicates that lower serum level of estradiol
 may represent higher predisposition for development of ESCC, and ERβ expression and/or nuclear location may predict better
 outcome for patients with ESCC. The present results provide clues to explain the striking gender difference for ESCC, which
 warrants further investigations on potential applications of estrogen or analogs in prevention of ESCC.
 
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s12032-010-9457-8Authors
		Qi-Ming Wang, Zhengzhou University Department of Oncology, The First Affiliated Hospital 450052 Zhengzhou, Henan People’s Republic of ChinaYi-Jun Qi, Henan University Key Laboratory of Cellular and Molecular Immunology, Institute of Immunology, College of Medicine 475000 Kaifeng, Henan Peop...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3328334</comments>
            <pubDate>Tue, 02 Mar 2010 10:07:46 +0100</pubDate>
            <guid isPermaLink="false">3328334</guid>        </item>
        <item>
            <title>CYP2E1 Rsa I/Pst I polymorphism and esophageal cancer risk: a meta-analysis based on 1,088 cases and 2,238 controls</title>
            <link>http://www.medworm.com/index.php?rid=3328336&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm47540128544n224%2F</link>
            <description>In conclusion, our meta-analysis demonstrates that CYP2E1 Rsa I/Pst I c2 allele may be a decreased risk factor
 for developing esophageal cancer among Asians populations.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9455-xAuthors
		Yuming Niu, Nanjing Medical University Institute of Dental Research 140 Hanzhong Road 210029 Nanjing People’s Republic of ChinaHua Yuan, Nanjing Medical University Institute of Dental Research 140 Hanzhong Road 210029 Nanjing People’s Republic of ChinaWeidong Leng, Taihe Hospital, Yunyang Medical College Department of Stomatology 32 South Renmin Road 442000 Shiyan People’s Republic of ChinaYongchu Pang, Nanjing Medical University Institute of Dental Research 140 Hanzhong Road 210029 Nanjing People’s Republic of ChinaNing...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3328336</comments>
            <pubDate>Tue, 02 Mar 2010 10:07:45 +0100</pubDate>
            <guid isPermaLink="false">3328336</guid>        </item>
        <item>
            <title>Primary adult soft tissue sarcomas: analysis of 294 patients</title>
            <link>http://www.medworm.com/index.php?rid=3308148&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F50023476n2179lg4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We retrospectively analyzed 294 patients with primary soft tissue sarcoma followed between 1996 and 2002 in Ankara Oncology
 Hospital. There were 170 male and 124 female patients with the age range of 16–80&amp;nbsp;years. The primary tumor was in the extremity
 in 72.9% of the patients. We determined lung metastasis in 102 (85%) out of the 120 patients as distant metastasis. The most
 common adult sarcomas were liposarcoma (16.3%), malignant mesenchymal tumor (MMT) (13.9%), malignant fibrous histiocytoma
 (MFH) (11.2%), rhabdomyosarcoma (10.2%) and synovial sarcoma (10.2%). Seventeen patients (5.3%) had grade 1 tumor, 143 patients
 (52.2%) had grade 2 tumor, and 112 patients (41.4%) had grade 3 tumor. In 45 patients (15.3%), the grade of the tumors is
 unknown. The tumor...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308148</comments>
            <pubDate>Wed, 24 Feb 2010 06:55:43 +0100</pubDate>
            <guid isPermaLink="false">3308148</guid>        </item>
        <item>
            <title>The evolution and impact of therapy in multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3291553&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F31t17juq27u75338%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Multiple myeloma is a clonal B-cell malignancy characterized by aberrant expression of plasma cells wtihin the bone marrow,
 and is associated with the well known clinical manifestations anemia, bone disease, renal dysfunction, hypercalcemia, and
 recurrent infections. For many years, melphalan and prednisone represented the standard of care in multiple myeloma therapy,
 with stem cell transplantation reserved for selected patients. Treatment of the disease has evolved rapidly over the past
 decade, however, with the development and utilization of thalidomide, lenalidomide, and bortezomib. As a result of these developments,
 clinical outcomes have improved significantly. This review highlights important historic landmarks as well as more recent
 events that have played ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3291553</comments>
            <pubDate>Fri, 19 Feb 2010 06:44:43 +0100</pubDate>
            <guid isPermaLink="false">3291553</guid>        </item>
        <item>
            <title>Brucellosis: a rare cause of febrile neutropenia in acute myeloblastic leukemia</title>
            <link>http://www.medworm.com/index.php?rid=3291554&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2852448766666312%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Brucellosis is a zoonotic disease and endemically seen in the Middle East, Eastern Europe and continental America. Febrile
 neutropenia related to Brucellosis has been reported only in a few cases. Brucella was cultured from the bone morrow of a
 42-year-old woman who was admitted to hospital with symptoms of fever and fatigue and later diagnosed as acute myeloblastic
 leukemia (AML). The patient was treated for both AML and Brucellosis without any problems and discharged from the hospital
 after scheduling her follow-up visits. Brucellosis might be considered in the etiology of febrile neutropenia in endemic regions
 and must be treated effectively to prevent possible morbidity and mortality during or after chemotherapy.
 
 
	Content Type Journal ArticleCategory Origin...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3291554</comments>
            <pubDate>Fri, 19 Feb 2010 06:44:41 +0100</pubDate>
            <guid isPermaLink="false">3291554</guid>        </item>
        <item>
            <title>Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells</title>
            <link>http://www.medworm.com/index.php?rid=3289102&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh352683up8307566%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ginseng polysaccharide has anticancer activity. However, the structure–activity relationship and the activity mechanism are
 still unclear. Therefore, it is necessary to study the anticancer activity of structurally different ginseng polysaccharide
 fractions and their potential mechanisms. Ginseng polysaccharide fractions and their temperature-modified products were assayed
 for their effects on HT-29 cell proliferation by MTT assay, on cell cycle progression by flow cytometry, and on caspase-3
 activation by western blot analysis. The HG-rich ginseng pectin inhibited cell proliferation and induced cell cycle arrest
 in the G2/M phase. The temperature-modified HG-rich pectin had dramatically increased antiproliferative effect and induced
 apoptosis accompanied by the...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3289102</comments>
            <pubDate>Thu, 18 Feb 2010 06:53:01 +0100</pubDate>
            <guid isPermaLink="false">3289102</guid>        </item>
        <item>
            <title>Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study</title>
            <link>http://www.medworm.com/index.php?rid=3289103&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1w1428tt54860436%2F</link>
            <description>In conclusion, these algorithms can be used effectively
 in Chinese patients with DLBCL.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9433-3Authors
		Zi Chen, Fudan University Department of Hematology, Huashan Hospital 200040 Shanghai ChinaZunguo Du, Fudan University Department of Pathology, Huashan Hospital 200040 Shanghai ChinaJieqing Chen, The University of Texas M.D. Anderson Cancer Center Department of Melanoma Houston TX 77030 USAZhongqing Chen, Fudan University Department of Pathology, Huashan Hospital 200040 Shanghai ChinaYun Bao, Fudan University Department of Pathology, Huashan Hospital 200040 Shanghai ChinaFeng Tang, Fudan University Department of Pathology, Huashan Hospital 200040 Shanghai China
	

	
		Journal Medical OncologyOnline ISSN 1559-1...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3289103</comments>
            <pubDate>Thu, 18 Feb 2010 06:53:00 +0100</pubDate>
            <guid isPermaLink="false">3289103</guid>        </item>
        <item>
            <title>The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=3273560&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft1617027g3576677%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Thymic hyperplasia is a common phenomenon in both children and young adults after chemotherapy and may explain the finding
 of a mediastinal mass in patients with malignant lymphoma after complete remission. In the present study, we report 5 cases
 with malignant lymphoma presenting with a mediastinal mass on CT scan after completion of chemotherapy diagnosed as thymic
 hyperplasia by PET-CT imaging. We retrospectively analyzed 5 patients who presented with anterior mediastinal masses a median
 of 4&amp;nbsp;months (range 3–6) after achieving complete remission following successful treatment for malignant lymphoma. Three patients
 were diagnosed with Hodgkin’s lymphoma (HL) and the others with non-Hodgkin’s lymphoma (NHL). The median age of the patients
 was 23 (range...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3273560</comments>
            <pubDate>Sat, 13 Feb 2010 06:51:39 +0100</pubDate>
            <guid isPermaLink="false">3273560</guid>        </item>
        <item>
            <title>Allogeneic blood transfusion in patients in Dukes B stage of colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=3270410&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F898188p10771j5u3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study is to evaluate influence of allogeneic blood transfusion on prognosis in patients in Dukes B stage of
 colorectal cancer. All patients with colorectal cancer who were admitted at our Department of Surgery between January 2000
 and December 2004 were analyzed. One hundred fifty-one patients who fulfilled inclusion criteria were enrolled in further
 evaluation. B stage according to Dukes classification and curative resection were inclusion criteria. Exclusion criteria were
 polyposis syndromes, nonpolyposis syndromes, inflammatory bowel disease, autoimmune disease and previous blood transfusion.
 Patients were divided into two groups: Group 1 received ≤3 units of allogeneic blood transfusion and group 2 received &amp;gt;3 units
 of allogeneic blood tra...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270410</comments>
            <pubDate>Fri, 12 Feb 2010 07:32:50 +0100</pubDate>
            <guid isPermaLink="false">3270410</guid>        </item>
        <item>
            <title>Suppression of Na+/H+ exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion</title>
            <link>http://www.medworm.com/index.php?rid=3270411&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp842522x7440w641%2F</link>
            <description>In this study, we also found that NHE1
 is over-expressed in HCC cell lines. Subsequently, we silenced NHE1 expression in the human HCC cell line SMMC-7721 using
 RNA interference (RNAi) and examined the invasiveness and proliferation of NHE1-silenced SMMC-7721 cells and the matrix metalloproteinase-2
 (MMP-2) activity. The knockdown of NHE1 expression significantly inhibited the invasive ability of SMMC-7721 cells but had
 only a minor effect on the cellular proliferation rate. Moreover, NHE1 knockdown significantly reduced the secretion of MMP-2.
 Further experiment using amiloride (an inhibitor of NHE1) confirmed the above result. Together, these findings indicate that
 NHE1 has an important role in SMMC-7721 cell invasion and that NHE1 might be a new target of HCC treatment.
 
	Content...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270411</comments>
            <pubDate>Fri, 12 Feb 2010 07:32:48 +0100</pubDate>
            <guid isPermaLink="false">3270411</guid>        </item>
        <item>
            <title>Prognostic significance of telomerase activity and some tumor markers in non-small cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3263918&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5n8j22p0281604g1%2F</link>
            <description>The objective of
 the current study was to assess the prognostic significance of telomerase activity, serum anti-p53 antibodies (anti-p53a),
 c-erbB-2 and CEA in patients with NSCLC. The study included 60 patients with histological proven NSCLC besides 60 controls
 (30 smokers and 30 nonsmokers). Patients were divided into four stages according to their histopathology. All patients were
 subjected to; determination of telomerase activity by telomeric repeat amplification protocol (TRAP) assay in tumor tissue
 specimens and adjacent normal lung tissues, also, determination of preoperative serum anti-p53a, c-erbB-2 and CEA. Telomerase
 activity was detected in 40 of 60 (66.6%) of NSCLC tissue specimens using the TRAP assay. As regard the stages, telomerase
 activity was positive in 5 of 15 p...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3263918</comments>
            <pubDate>Wed, 10 Feb 2010 06:50:14 +0100</pubDate>
            <guid isPermaLink="false">3263918</guid>        </item>
        <item>
            <title>Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3263920&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgu66wn4u5g212h60%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Esophageal squamous cell carcinoma (ESCC) is one of the most frequently diagnosed malignant tumors in North China. We have
 identified that Wnt2/β-catenin pathway is activated in ESCC cells and sodium nitroprusside (SNP) and siRNA against β-catenin
 not only inhibit the expressions of β-catenin and its major downstream effectors including c-myc and cyclin D1 but induce
 cell cycle arrest and apoptosis. The purpose of the present study was to analyze the relationship between pathological parameters
 including invasion depth and lymph node metastasis and the expressions of β-catenin, c-myc, and cyclin D1 in order to evaluate
 their values of prognosis in patients with ESCC. The expressions of β-catenin, c-myc, and cyclin D1 were detected immunohistochemically
 in the...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3263920</comments>
            <pubDate>Tue, 09 Feb 2010 06:48:27 +0100</pubDate>
            <guid isPermaLink="false">3263920</guid>        </item>
        <item>
            <title>Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=3263919&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq1p7gn23264j7235%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung
 cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a
 meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society
 of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy,
 evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis.
 For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T
 and T/T genotype...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3263919</comments>
            <pubDate>Tue, 09 Feb 2010 06:48:27 +0100</pubDate>
            <guid isPermaLink="false">3263919</guid>        </item>
        <item>
            <title>miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines</title>
            <link>http://www.medworm.com/index.php?rid=3263921&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy7870t0744282181%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;MicroRNAs (miRNAs) are endogenous small noncoding RNA molecules involved in modulation of cellular sensitivity to anti-cancer
 drugs. miRNA-21 (miR-21), one of the most prominent miRNAs in the genesis and progression of many human cancers, has been
 rarely characterized in myelogenous leukemia. Arsenic trioxide (ATO) was successfully used in the treatment of acute promyelocytic
 leukemia (APL) etc. However, cytotoxicity or insensitivity is a major concern in the successful treatment of leukemia. Here,
 we used a specific precursor miRNA-21 (pre-miR-21) or anti-miRNA-21 oligonucleotide (AMO-miR-21) to study sensitivity of HL60
 and K562 cells to ATO. Cell viability and cell cycle were evaluated by MTT assay and PI assay using flow cytometry, respectively.
 Levels of miR-...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3263921</comments>
            <pubDate>Tue, 09 Feb 2010 06:48:26 +0100</pubDate>
            <guid isPermaLink="false">3263921</guid>        </item>
        <item>
            <title>Concomitant Hodgkin’s lymphoma and gastric adenocarcinoma: a rare coincidence</title>
            <link>http://www.medworm.com/index.php?rid=3263922&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fpx77126871675563%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gastric adenocarcinomas may be seen together with colon, prostate, breast, liver, lung and gynecological malignancies as synchronous
 or metachronous cancer. However, Hodgkin’s lymphoma (HL) is rarely diagnosed with solid tumors. Herein, a 72-year-old man
 with both gastric adenocarcinoma and HL has been presented. Mass lesions far away from the primary tumor in cancer patients
 can be not only the sign of distant metastasis but also another primary malignancy. In the English literature, synchronous
 gastric adenocarcinoma and HL has been rarely reported, and as far as we know, this is the third case to be reported.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9439-xAuthors
		Ü. Yalçıntaş Arslan, Ankara Oncology Education and Resear...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3263922</comments>
            <pubDate>Tue, 09 Feb 2010 06:48:25 +0100</pubDate>
            <guid isPermaLink="false">3263922</guid>        </item>
        <item>
            <title>Acute promyelocytic leukemia in a young patient with breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=3255858&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgx466512149q138m%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s12032-010-9437-zAuthors
		Ozgur Kara, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye Ankara 06100 TurkeyEvren Ozdemir, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye Ankara 06100 TurkeyCagatay Arslan, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye Ankara 06100 TurkeyErkan Dogan, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye Ankara 06100 TurkeyKadri Altundag, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye Ankara 06100 Turkey
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3255858</comments>
            <pubDate>Sat, 06 Feb 2010 08:23:40 +0100</pubDate>
            <guid isPermaLink="false">3255858</guid>        </item>
        <item>
            <title>Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours</title>
            <link>http://www.medworm.com/index.php?rid=3247914&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu203n6k4555011t1%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s12032-010-9438-yAuthors
		Azhar B. Ali, National University of Singapore Cancer Science Institute (CSI) Singapore 28 Medical Drive, Centre for Life Sciences (CeLS) Singapore 117456 SingaporePhilip T. C. Iau, National University Hospital Department of Surgery Singapore SingaporeJen-Hwei Sng, National University of Singapore Department of Surgery, Yong Loo Lin School of Medicine Singapore Singapore
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3247914</comments>
            <pubDate>Fri, 05 Feb 2010 08:14:18 +0100</pubDate>
            <guid isPermaLink="false">3247914</guid>        </item>
        <item>
            <title>Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas</title>
            <link>http://www.medworm.com/index.php?rid=3247915&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk248551683367336%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;JAK/STAT pathway transmits signals from the cell membrane to the nucleus in response to extracellular growth factors and cytokines.
 Activation of this pathway has been found in certain types of human tumors. The goal of this study was to investigate the
 correlation between the JAK/STAT pathway in human gliomas and patients’ prognosis, which currently is unknown. Western blotting
 analysis and immunohistochemical staining were performed to detect JAK-1, phosphorylated JAK-1, and STAT-3 expression patterns
 in the biopsies from 96 patients with primary gliomas. Kaplan–Meier survival and Cox regression analyses were performed to
 evaluate the prognosis of patients. Western blotting analysis and immunohistochemical staining both indicated that the expression
 levels o...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3247915</comments>
            <pubDate>Fri, 05 Feb 2010 08:14:12 +0100</pubDate>
            <guid isPermaLink="false">3247915</guid>        </item>
        <item>
            <title>Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells</title>
            <link>http://www.medworm.com/index.php?rid=3240909&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff0554nu87326231t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Curcumol isolated from Rhizoma Curcumae, a common traditional Chinese medicine, has been reported to possess antitumor effects,
 but little is known about the molecular mechanism. The current study tried to explore the molecular mechanism of curcumol-induced
 cell death in human lung adenocarcinoma (ASTC-a-1) cells. Cell counting kit (CCK-8) assay, fluorescence resonance energy transfer
 (FRET), confocal fluorescence microscopy imaging, emission spectral analysis, and flow cytometry (FCM) technologies were used
 to assess the characteristics of curcumol-induced cell death. FCM analysis showed that curcumol induced G2/M phase arrest, nuclear fragmentation and phosphatidylserine externalization, implying that curcumol dominantly induced apoptotic
 cell death. Dynamical im...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3240909</comments>
            <pubDate>Wed, 03 Feb 2010 06:56:09 +0100</pubDate>
            <guid isPermaLink="false">3240909</guid>        </item>
        <item>
            <title>Osteolytic lesions marker in multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3240910&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F543w78m77gv01475%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The degradation product of collagen type I carboxy terminal telopeptide (ICTP) represents a new biochemical parameter that
 reflects the changes in the resorption properties of skeletal system. Affection of the skeleton is one of the most important
 characteristics of multiple myeloma (MM). We estimated significance of ICTP as osteolysis predictor and overall survival in
 comparison with standard prognostic parameters β2-microglobulin and C-reactive protein (CRP), in patients with MM. With our results, we have shown significant difference in
 serum level of ICTP (P&amp;nbsp;=&amp;nbsp;0.009) between patients with and without osteolysis on conventional radiography. It was proved that ICTP is the most significant
 predictor of osteolysis (P&amp;nbsp;=&amp;nbsp;0.09), while CRP is the mo...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3240910</comments>
            <pubDate>Tue, 02 Feb 2010 07:00:59 +0100</pubDate>
            <guid isPermaLink="false">3240910</guid>        </item>
        <item>
            <title>Pancreatic panniculitis as the first manifestation of the pancreatic involvement during the course of a gastric adenocarcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3228569&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm3302142g524r606%2F</link>
            <description>We present a 69-year-old
 male patient of gastric carcinoma with PP. The literature is reviewed, clinical and histological features of the case are
 discussed. This is the first case of PP in a gastric carcinoma patient reported in literature. As a conclusion, PP can be
 the first manifestation of a pancreatic metastasis of any carcinoma.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9420-8Authors
		H. Beyazıt, American Hospital Dermatology Department Güzelbahçe sok. No. 20 34365 Istanbul Nişantaşı TurkeyO. Aydin, ETA Pathology Lab Akkavak Sok. Dilek Ap No. 22/3 34365 Tesvikiye Istanbul TurkeyC. Demirkesen, ETA Pathology Lab Akkavak Sok. Dilek Ap No. 22/3 34365 Tesvikiye Istanbul TurkeyD. Derin, American Hospital Medical Oncology Department Güzelbahçe...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3228569</comments>
            <pubDate>Sat, 30 Jan 2010 18:16:18 +0100</pubDate>
            <guid isPermaLink="false">3228569</guid>        </item>
        <item>
            <title>Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro</title>
            <link>http://www.medworm.com/index.php?rid=3223979&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy9560732200tp1wq%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The p27Kip1 cyclin-dependent kinase inhibitor is a negative regulator of cell cycle progression in G1 phase; recent studies suggested that oncogenically activated kinase Akt/PKB can also phosphorylate p27kip1 at T157 inducing its relocalization to the cytoplasm. To evaluate the significance of p-p27 Thr157 and PI3K pathway in hepatocellular
 carcinoma (HCC), we studied 51 hepatocellular carcinomas along with corresponding nontumoral tissue and the HCC cell lines.
 Immunohistochemistry and western blot analysis suggested that p-p27 Thr157 was overexpressed in HCC, which was positively
 correlated with proliferation marker Ki-67. Correlation analysis was performed among immunohistochemistry-assessed level of
 p-p27 Thr157, survival, and major clinical and pathological var...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223979</comments>
            <pubDate>Thu, 28 Jan 2010 06:54:00 +0100</pubDate>
            <guid isPermaLink="false">3223979</guid>        </item>
        <item>
            <title>Autophagy modification augmented the treatment effects initiated by arsenic trioxide in NB4 cells</title>
            <link>http://www.medworm.com/index.php?rid=3223981&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd3568148m8764574%2F</link>
            <description>This study was designed to examine the role of autophagy in the death of human acute promyelocytic leukemia NB4
 cells initiated by arsenic trioxide. Furthermore, the effects of autophagy inhibition and augmentation on cell viability were
 also compared. Our data suggested that both augmentation and suppression of autophagy could enhance the treatment effects
 while the latter was preferable. This study indicated that autophagy regulation augmented the treatment effects initiated
 by arsenic trioxide in NB4 cells, and that the selection of regulator should be precisely considered.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9430-6Authors
		YaLi Ren, Peking University First Hospital Lab of Electron Microscopy No. 8 Xishiku Street, XiCheng District 100034 Bei...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223981</comments>
            <pubDate>Wed, 27 Jan 2010 20:00:24 +0100</pubDate>
            <guid isPermaLink="false">3223981</guid>        </item>
        <item>
            <title>Home parenteral nutrition (HTPN) for incurable patients with cancer with gastrointestinal obstruction: do the benefits outweigh the risks?</title>
            <link>http://www.medworm.com/index.php?rid=3223980&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw20xh8w4k8327g75%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients with cancer may suffer from malnutrition due to cachexia, this maybe secondary to treatment, psychological factors
 and/or gastrointestinal (GI) obstruction. GI obstruction indicates a need for TPN. Does this apply to patients with incurable
 terminal cancer? How does TPN affect longevity and quality of life in this group of patients? What is the course of TPN treatment
 compared with patients receiving TPN due to nonmalignant GI failure (NMGIF). The aim of this work was to help define the role
 of TPN in patients with incurable cancer and GI obstruction. Data of all patients treated by home TPN (HTPN) 2003–2009 were
 collected prospectively and analyzed. Sixty-eight patients were treated with HTPN, 30 of them for NMGIF. Mean age was 52&amp;nbsp;years
 (37–87)....</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223980</comments>
            <pubDate>Wed, 27 Jan 2010 20:00:24 +0100</pubDate>
            <guid isPermaLink="false">3223980</guid>        </item>
        <item>
            <title>Unusual presentation of desmoid tumor in the small intestine: a case report</title>
            <link>http://www.medworm.com/index.php?rid=3223983&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv11m3u1m3114n152%2F</link>
            <description>We report a 50-year-old man who presented with the sudden
 onset of severe abdominal pain. Computerized tomography (CT) demonstrated a huge homogeneous tumor in the lower abdomen that
 appeared to be in continuity with the distal ileum. The mass adherent to the ileum was resected and proved to be a desmoid
 tumor. The patient has remained recurrence free on follow-up.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9429-zAuthors
		Ching-Wei Chang, Mackay Memorial Hospital, Mackay Medicine, Nursing and Management College Division of Gastroenterology, Department of Internal Medicine No. 92, Sec. 2, Chung Shan North Road Taipei TaiwanTsang-En Wang, Mackay Memorial Hospital, Mackay Medicine, Nursing and Management College Division of Gastroenterology, Department of...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223983</comments>
            <pubDate>Wed, 27 Jan 2010 20:00:23 +0100</pubDate>
            <guid isPermaLink="false">3223983</guid>        </item>
        <item>
            <title>Vascular endothelial growth factor-A and -C: expression and correlations with lymphatic metastasis and prognosis in colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=3223982&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F560368210511075q%2F</link>
            <description>In conclusion, increased expression of VEGF-A and VEGF-C in marginal portion of colorectal cancer was correlated
 with lymph node metastasis. VEGF-C facilitates colorectal cancer cells invade into peritumoral lymphatic vessels, and different
 mechanisms may exist in the invasion of tumor cells into peritumoral and intratumoral lymphatic vessels. Assessment the expression
 of both VEGF-A and VEGF-C in the marginal portion of tumor may help to identify patients with colorectal cancer with unfavourable
 overall survival.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9427-1Authors
		Mei Lin, Qingdao Municipal Hospital Laboratory Medicine Qingdao ChinaHui-zhong Lin, Qingdao Municipal Hospital Department of Surgery Qingdao ChinaShu-pei Ma, Qingdao Municipal Hospita...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223982</comments>
            <pubDate>Wed, 27 Jan 2010 20:00:23 +0100</pubDate>
            <guid isPermaLink="false">3223982</guid>        </item>
        <item>
            <title>Detection of a new embryonic antigen (ESA-10) in the blood of patients with cancer: preliminary results in the United States</title>
            <link>http://www.medworm.com/index.php?rid=3223984&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc878r4gu781v5441%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;ESA-10 is an embryonic antigen expressed by tumor cells. A method to detect the antigen in the blood based on alterations
 in the erythrocyte sedimentation rate that occur when antiserum to ESA-10 is bound to the antigen in blood was devised and
 used here to determine the sensitivity and predictive value of the test in patients with biopsy proven non-hematologic malignancies,
 and in normal control subjects. The test was positive in 22 of 24 cancer patients tested, and negative in 30 of 35 control
 subjects. Of the five positive control subjects, one female had recently given birth and was lactating. Another control subject
 was recently diagnosed with prostate cancer, just months after having participated in this study. Therefore, this tumor marker
 test (Turtest®) h...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223984</comments>
            <pubDate>Wed, 27 Jan 2010 20:00:22 +0100</pubDate>
            <guid isPermaLink="false">3223984</guid>        </item>
        <item>
            <title>WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval</title>
            <link>http://www.medworm.com/index.php?rid=3223985&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk42r164t52517588%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although antigen-specific immune responses including cytotoxic T cells (CTLs) against antigen peptide could be enhanced after
 tumor antigen peptide vaccinations, the immune responses do not necessarily result in a decrease or eradication of tumor cells
 in the vaccination trials. We focused on whether antigen-specific CTLs could be damaged by the repeated stimulation of antigenic
 peptide and whether regulatory T (Treg) cells would be increased by the administration of WT1 peptide. We administered WT1
 peptide 22 times over 18&amp;nbsp;months in a CML patient who was being treated with imatinib. Although WT1 peptide administration
 every 2&amp;nbsp;weeks did not show any beneficial effects on the minimal residual disease (copies of bcr-abl transcripts), the transcripts
 remark...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3223985</comments>
            <pubDate>Wed, 27 Jan 2010 20:00:21 +0100</pubDate>
            <guid isPermaLink="false">3223985</guid>        </item>
        <item>
            <title>A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review</title>
            <link>http://www.medworm.com/index.php?rid=3205717&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1715276u15756059%2F</link>
            <description>In conclusion, the NAT1 or NAT2 phenotypes
 detoxify carcinogens and their reactive intermediates are unlikely to be the cause of PCa development.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9423-5Authors
		Chunming Gong, The First Affiliated Hospital of Guangxi Medical University Department of Urology Nanning, Guangxi Zhuang Autonomous Region 530021 People’s Republic of ChinaXueying Hu, The First Affiliated Hospital of Guangxi Medical University Department of Urology Nanning, Guangxi Zhuang Autonomous Region 530021 People’s Republic of ChinaYong Gao, The First Affiliated Hospital of Guangxi Medical University Department of Urology Nanning, Guangxi Zhuang Autonomous Region 530021 People’s Republic of ChinaYunfei Cao, The First Affiliated Hospital of G...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3205717</comments>
            <pubDate>Sat, 23 Jan 2010 07:49:13 +0100</pubDate>
            <guid isPermaLink="false">3205717</guid>        </item>
        <item>
            <title>Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=3205718&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F812q075704103458%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recent studies have shown some degrees of discordance in ER, PR and HER-2 immunohistochemical expression between primary and
 recurrent/metastatic lesions (RML). Analysis was made on 78 patients with MBC whose ER, PR and/or HER-2 status were known
 both on the tissue samples of primary and RML. Among the RML sites, 29.5% were locoregional, 70.5% were distant metastatic
 sites. Among 75 patients with known ER expression on both primary and RML, 36% (n&amp;nbsp;=&amp;nbsp;27) showed discordance on ER expression. Among 72 patients with known PR expression on both primary and RML, 54.2% (n&amp;nbsp;=&amp;nbsp;39) showed discordance on PR expression. Among 61 patients with known HER-2 expression on both primary and RML, 14.7% (n&amp;nbsp;=&amp;nbsp;9) showed discordance on HER-2 expression. No diff...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3205718</comments>
            <pubDate>Sat, 23 Jan 2010 07:49:12 +0100</pubDate>
            <guid isPermaLink="false">3205718</guid>        </item>
        <item>
            <title>A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib</title>
            <link>http://www.medworm.com/index.php?rid=3205719&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fer5445v11l541217%2F</link>
            <description>We report a case of a 66-year-old Taiwanese female patient with situs ambiguus diagnosed of pancreatic head cancer. She was
 treated with gemcitabine and erlotinib and remained in stable disease on follow-up imaging studies. Situs ambiguus is a rare
 disease and reports of such patients with cancer have rarely been reported in the literature. Our case illustrates that standard
 chemotherapy in this group of patients may be undergone with promising results.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-010-9421-7Authors
		Po-Chou Lin, National Yang-Ming University School of Medicine Taiwan Republic of ChinaJiun-I Lai, National Yang-Ming University School of Medicine Taiwan Republic of ChinaCheng-Hwai Tzeng, National Yang-Ming University School of Medicine Taiwan R...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3205719</comments>
            <pubDate>Fri, 22 Jan 2010 09:56:33 +0100</pubDate>
            <guid isPermaLink="false">3205719</guid>        </item>
        <item>
            <title>Epithelioid trophoblastic tumor: a clinicopathological and immunohistochemical study of seven cases</title>
            <link>http://www.medworm.com/index.php?rid=3194981&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp8217u5j4120245v%2F</link>
            <description>The objective of this study is to evaluate the clinicopathological features and immunohistochemical characteristics of epithelioid
 trophoblastic tumor (ETT). Seven cases of epithelioid trophoblastic tumor treated in the Women’s Hospital of Zhejiang University
 from 2004 September to 2008 December were retrospectively analyzed. Immunohistochemical study was performed. The most common
 presenting symptom was vaginal bleeding. Four patients had prior evidence of molar pregnancy and three patients presented
 with metastases. Mean age at diagnosis was 34.7&amp;nbsp;years. Mean pregnancy interval was 3.39&amp;nbsp;years. Human chorionic gonadotropin
 levels were 33.25–174315.5&amp;nbsp;IU/l. One case died from metastasis in lungs. The remaining six patients survived without recurrence.
 Immunohistochem...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3194981</comments>
            <pubDate>Wed, 20 Jan 2010 06:48:06 +0100</pubDate>
            <guid isPermaLink="false">3194981</guid>        </item>
        <item>
            <title>Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review</title>
            <link>http://www.medworm.com/index.php?rid=3194980&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F86467635011702q1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cytotoxic chemotherapy offers a modest benefit for patients with advanced non-small cell lung cancer (NSCLC), with response
 rates of 20–35% and median survival of 10–12&amp;nbsp;months. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs),
 gefitinib and erlotinib are active against lung cancer. In retrospective studies, EGFR-TKI therapy among patients harboring
 EGFR mutations showed response rates higher than 65% and a median survival of 20–30&amp;nbsp;months. Gefitinib is well tolerated and
 less toxic compared to conventional cytotoxic drugs, but gefitinib-related interstitial lung disease (ILD) has been reported
 as a serious adverse effect. Although the mechanism remains unknown, multivariate analysis revealed male sex, history of smoking,
 and...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3194980</comments>
            <pubDate>Wed, 20 Jan 2010 06:48:06 +0100</pubDate>
            <guid isPermaLink="false">3194980</guid>        </item>
        <item>
            <title>The association between interleukin-10-592 polymorphism and gastric cancer risk: a meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=3194982&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp019r51526773416%2F</link>
            <description>The objective
 of this study was to quantitatively evaluate the association between IL-10-592 allele polymorphism and gastric cancer susceptibility.
 We performed an extensive search of relevant studies and made a meta-analysis, including 12 studies with 2,285 gastric cancer
 cases and 4,236 controls. The combined results based on all studies showed that there were no significant differences in genotype
 distribution between gastric cancer cases and controls, CC versus CA/AA (OR&amp;nbsp;=&amp;nbsp;1.05, 95% CI: 0.92–1.18), CC/CA versus AA (OR&amp;nbsp;=&amp;nbsp;1.16,
 95% CI: 0.92–1.46), CC versus CA (OR&amp;nbsp;=&amp;nbsp;1.03, 95% CI: 0.90–1.17), CC versus AA (OR&amp;nbsp;=&amp;nbsp;1.10, 95% CI: 0.90–1.34), and CA versus
 AA (OR&amp;nbsp;=&amp;nbsp;1.16, 95% CI: 0.92–1.45). When stratifying for the race, it was f...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3194982</comments>
            <pubDate>Wed, 20 Jan 2010 06:48:05 +0100</pubDate>
            <guid isPermaLink="false">3194982</guid>        </item>
        <item>
            <title>Investigation of human papillomavirus DNA in colorectal carcinomas and adenomas</title>
            <link>http://www.medworm.com/index.php?rid=3190438&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp0u44565x6j55vk0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Human papillomavirus (HPV) has been considered to be an etiological agent for anogenital cancers, such as cervical cancer
 and possibly a subset of cancers of the aerodigestive tract. The aim of the study was to evaluate the presence of human papillomavirus
 DNA in colorectal carcinomas and adenomas. Formalin-fixed and paraffin-embedded archival tissue samples were used for DNA
 extraction. One hundred and six colorectal carcinomas and 62 adenomas were screened by nested polymerase chain reaction (PCR)
 for HPV DNA with a control group of 49 cervical tissues with invasive cervical carcinoma and cervical intraepithelial neoplasia
 (CIN). In the study group, we did not find HPV DNA positivity in any of all the colorectal carcinomas and adenomas. In the
 control group with...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190438</comments>
            <pubDate>Sat, 16 Jan 2010 06:52:51 +0100</pubDate>
            <guid isPermaLink="false">3190438</guid>        </item>
        <item>
            <title>Expression of cyclin D2, P53, Rb and ATM cell cycle genes in brain tumors</title>
            <link>http://www.medworm.com/index.php?rid=3190440&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F26k647885442738j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cyclin D2, P53, Rb and ATM as cell cycle genes regulate cell growth and proliferation. Considering their roles, we assumed
 that they have different level of mRNA expression in different grades of brain tumors. To determine this point, we investigated
 the mRNA expression in two types of brain tumors, including astrocytoma and meningioma. The mRNA of 52 brain tumor samples
 were extracted; cyclin D2, P53, Rb and ATM mRNA expression was quantified using the real-time quantitative reverse-transcription
 polymerase chain reaction. We compared mRNA expression of these genes between astrocytoma and meningioma tumors and also between
 different grades of them. Cyclin D2, P53, Rb and ATM had higher expression in astrocytoma than meningioma tumors. Higher grade
 (III and IV) of...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190440</comments>
            <pubDate>Fri, 15 Jan 2010 00:47:54 +0100</pubDate>
            <guid isPermaLink="false">3190440</guid>        </item>
        <item>
            <title>Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China</title>
            <link>http://www.medworm.com/index.php?rid=3190439&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa044602784l4h282%2F</link>
            <description>This study compared
 clinical and pathological characteristics of screen-detected and clinically diagnosed prostate cancers and evaluated the effectiveness
 of PSA screening for early detection of prostate cancer in Nanjing. Between July 2004 and December 2005, 8,562 men aged ≥50&amp;nbsp;years
 were included for PSA screening. Participants with serum PSA ≥4.0&amp;nbsp;ng/ml were recommended for transrectal ultrasonography (TRUS)-guided
 prostate needle biopsy (TRNB). During the same period, 82 consecutive clinically diagnosed prostate cancers were included
 as controls. The clinical and pathological features of the screened versus clinically diagnosed cancers were evaluated. A
 total of 719 (8.4%) of screened men had PSA levels ≥4.0&amp;nbsp;ng/ml. Biopsy was performed in 295 men, and 58 prosta...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190439</comments>
            <pubDate>Fri, 15 Jan 2010 00:47:54 +0100</pubDate>
            <guid isPermaLink="false">3190439</guid>        </item>
        <item>
            <title>Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=3190441&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7561l4597030350%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Combination chemotherapy of S-1 and cisplatin has shown promising activity against advanced gastric cancer, but the schedules
 and dose intensities of S-1 and cisplatin have not been consistent in several clinical trials. We investigated the efficacy
 and toxicity of 3-weekly S-1/cisplatin chemotherapy as first-line treatment in metastatic or relapsed gastric cancer (MRGC).
 Forty-six patients with MRGC were prospectively enrolled. S-1 (80&amp;nbsp;mg/m2/day; days 1–14) and cisplatin (60&amp;nbsp;mg/m2; day 1) were administrated every 3&amp;nbsp;weeks. Among 46 patients who received chemotherapy, one achieved a complete response and
 21 achieved a partial response, resulting in an overall response rate (RR) of 48%. Thirteen patients (28%) had stable disease
 and eight patients (1...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3190441</comments>
            <pubDate>Fri, 15 Jan 2010 00:47:52 +0100</pubDate>
            <guid isPermaLink="false">3190441</guid>        </item>
        <item>
            <title>HLA-A and breast cancer in West Peninsular Malaysia</title>
            <link>http://www.medworm.com/index.php?rid=3177059&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg2m2m025872v03m2%2F</link>
            <description>In conclusion, HLA-A2, -A30 and A31 were associated with breast cancer.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9414-6Authors
		Pooi Pooi Leong, University Putra Malaysia Department of Pathology, Faculty of Medicine and Health Sciences 43400 Selangor MalaysiaRohaizak Muhammad, Universiti Kebangasaan Malaysia Medical Centre Department of Surgery, Faculty of Medicine 56000 Selangor MalaysiaNaqiyah Ibrahim, Universiti Kebangasaan Malaysia Medical Centre Department of Surgery, Faculty of Medicine 56000 Selangor MalaysiaSoon Keng Cheong, Universiti Tunku Abdul Rahman Faculty of Medicine and Health Sciences Bandar Sungei Long 43000 Selangor MalaysiaHeng Fong Seow, Victoria University School of Biomedical and Health Sciences, Faculty of Health, Engineering and...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3177059</comments>
            <pubDate>Wed, 13 Jan 2010 06:47:31 +0100</pubDate>
            <guid isPermaLink="false">3177059</guid>        </item>
        <item>
            <title>Diffuse large B-cell lymphoma of non-germinal center B-cell type of the heart in an immunocompetent woman: an autopsy case</title>
            <link>http://www.medworm.com/index.php?rid=3168590&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq283570676343u31%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Primary lymphoma of the heart is extremely rare and almost always occurs in immunodeficient persons. The author reports a
 very rare autopsy case of primary diffuse large B-cell lymphoma in an immunocompetent woman. A 55-year-old woman presented
 with chest pain and arrhythmia. Various imaging modalities including US, CT, MRI, and gallium-scintigraphy revealed a mass
 in the right atrium and pericardial effusion. No tumor formations were recognized in other organs. Pericardial effusion cytology
 revealed malignant large lymphoid cells of B-cell type positive for CD20. Laboratory data did not reveal immunosuppression,
 and human immunodeficiency virus was negative. Therefore, a clinical diagnosis of primary heart lymphoma was made. The patient
 was treated with chemo-rad...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3168590</comments>
            <pubDate>Tue, 12 Jan 2010 06:48:02 +0100</pubDate>
            <guid isPermaLink="false">3168590</guid>        </item>
        <item>
            <title>Anticancer effect of Lycium barbarum polysaccharides on colon cancer cells involves G0/G1 phase arrest</title>
            <link>http://www.medworm.com/index.php?rid=3168591&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg77t80428773w537%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colorectal cancer is one of the most common cancers worldwide. The anticancer effect of Wolfberry (Lycium barbarum) polysaccharide (LBP) on colon cancer cells is largely unknown. To investigate the growth effect of LBP on human colon cancer
 cell and its possible mechanisms, human colon cancer SW480 and Caco-2 cells were treated with 100–1,000&amp;nbsp;mg/l LBP for 1–8&amp;nbsp;days.
 Cell growth was measured by MTT assay and crystal violet assay. Distribution of the cell cycle was analyzed by flow cytometry.
 Western blotting was used to indicate changes in the level of cyclins and cyclin-dependent kinases (CDKs). LBP treatment inhibited
 both colon cancer cell lines in a dose-dependent manner. At concentrations from 400 to 1,000&amp;nbsp;mg/l, LBP significantly inhibited
 the...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3168591</comments>
            <pubDate>Tue, 12 Jan 2010 06:48:01 +0100</pubDate>
            <guid isPermaLink="false">3168591</guid>        </item>
        <item>
            <title>Education, economic status and other risk factors in gastric cancer: “a case–control study of Turkish oncology group”</title>
            <link>http://www.medworm.com/index.php?rid=3165032&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc0546407810341l7%2F</link>
            <description>In conclusion, the goal of obtaining comparable socioeconomic status by including the level of education in the
 matching criteria was not met in our study because of the difference in income level. The only risk reducing factor that was
 not in accordance with income level was the unexpectedly higher rate of bread consumption in control group.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9406-6Authors
		F. Icli, Ankara University School of Medicine Department of Medical Oncolocy Dikimevi 06590 Ankara TurkeyH. Akbulut, Ankara University School of Medicine Department of Medical Oncolocy Dikimevi 06590 Ankara TurkeyB. Yalcin, Ankara University School of Medicine Department of Medical Oncolocy Dikimevi 06590 Ankara TurkeyF. Ozdemir, Karadeniz Technical Universi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3165032</comments>
            <pubDate>Thu, 07 Jan 2010 15:59:35 +0100</pubDate>
            <guid isPermaLink="false">3165032</guid>        </item>
        <item>
            <title>Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells</title>
            <link>http://www.medworm.com/index.php?rid=3165033&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fku6pjj2563380313%2F</link>
            <description>In conclusion, our results suggest an association of lost expression of
 DCC with the ovarian cancer, and DCC gene may inhibit the growth of ovarian carcinoma cells. However, this result needs further trials with a larger sample.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9400-zAuthors
		Liu Meimei, The Second Affiliated Hospital of Harbin Medical University Department of Obstetrics and Gynaecology 150086 Harbin Hei Longjiang ChinaLi Peiling, The Second Affiliated Hospital of Harbin Medical University Department of Obstetrics and Gynaecology 150086 Harbin Hei Longjiang ChinaLi Baoxin, Harbin Medical University College of Pharmacy 150086 Harbin Hei Longjiang ChinaLi Changmin, The Second Affiliated Hospital of Harbin Medical University Department of Obstetri...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3165033</comments>
            <pubDate>Thu, 07 Jan 2010 15:59:34 +0100</pubDate>
            <guid isPermaLink="false">3165033</guid>        </item>
        <item>
            <title>Clear cell adenocarcinoma of the uterine cervix in a young pregnant woman: a case report with immunohistochemical study</title>
            <link>http://www.medworm.com/index.php?rid=3165034&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk53260v487476nlm%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The patient was a 30-year-old-pregnant woman (para 1, gradiva 1) without in utero exposure to diethylstilbestrol. A papillary
 and flat lesion was found by colposcopy in the uterine cervix in the routine examination at 10 pregnancy weeks. Biopsies showed
 papillary and tubular proliferation of malignant cells with clear glycogen-rich cytoplasm and malignant hobnail cells and
 were diagnosed as clear cell adenocarcinoma. The patient was treated by radical hysterectomy. The lesion of the cervix (10&amp;nbsp;×&amp;nbsp;15&amp;nbsp;×&amp;nbsp;5&amp;nbsp;mm)
 was clear cell adenocarcinoma with mild invasion into shallow myometrium (pTIb). An immunohistochemical study showed that
 the tumor cells were positive for pancytokeratins (AE1/3, CAM5.2, KL-1, and polyclonal wide), cytokeratin (CK) 7, ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3165034</comments>
            <pubDate>Thu, 07 Jan 2010 15:59:33 +0100</pubDate>
            <guid isPermaLink="false">3165034</guid>        </item>
        <item>
            <title>High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=3154313&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff548x63363u07855%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Because of improved therapeutic results after first-line platinum-based chemotherapy in patients with stage IV non-small-cell
 lung cancer (NSCLC), second-line chemotherapy may be considered for a growing number of patients. Approximately, 10% of patients
 have an interval time after concluding first-line platinum-based chemotherapy greater than 6&amp;nbsp;months. These patients may achieve
 high tumor responses when platinum is again used in second-line treatment. Twenty-three patients experiencing progression
 following 6 months after concluding platinum-based chemotherapy were managed with second-line treatment with carboplatin combined
 with gemcitabine or pemetrexed. Overall response, progression-free survival (PFS), and overall survival (OS) after initiation
 of secon...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154313</comments>
            <pubDate>Tue, 05 Jan 2010 06:51:33 +0100</pubDate>
            <guid isPermaLink="false">3154313</guid>        </item>
        <item>
            <title>Renal disorder preceding multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3154314&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn65j7tm0tu47875u%2F</link>
            <description>We report a case
 of 40-year-old female who first admitted to the hospital with symptoms and signs of weight loss, nausea and vomiting, and
 with findings of proteinuria renal dysfunction and anemia. Renal biopsy revealed light chain deposition and findings mimicking
 membranoproliferative glomerulonephritis (MPGN). Investigation of the patient for plasma cell dyscrasia was resulted in normal
 findings. After 28&amp;nbsp;months, she was re-evaluated and MM was diagnosed.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9404-8Authors
		Metin Isik, Ankara Numune Education and Research Hospital Department of Medical Oncology Sihhiye Ankara 06100 Turkey
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154314</comments>
            <pubDate>Tue, 05 Jan 2010 06:51:29 +0100</pubDate>
            <guid isPermaLink="false">3154314</guid>        </item>
        <item>
            <title>Primary lymphoma of bone: a case report and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=3154317&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl51j713hvt43w23x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of this study was to investigate the clinical signs and therapy of primary lymphoma of bone (PLB). One primary
 lymphoma of bone is described, and review of the pertinent literature is introduced. The patient achieved complete remission
 with no evidence of local recurrence. PLB are uncommon malignancies. Patients with PLB commonly present with local bone pain,
 soft tissue swelling and a mass or a pathological fracture. Most cases of PLB are classified as diffuse large B-cell lymphomas
 in the WHO classification of hematological malignancies. Comprehensive immunohistochemical studies are required to establish
 an accurate histological diagnosis of PLB. Early diagnosis and active treatment can improve the prognosis.
 
	Content Type Journal ArticleCategory Or...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154317</comments>
            <pubDate>Tue, 05 Jan 2010 06:51:28 +0100</pubDate>
            <guid isPermaLink="false">3154317</guid>        </item>
        <item>
            <title>Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population</title>
            <link>http://www.medworm.com/index.php?rid=3154316&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5524408741405120%2F</link>
            <description>The objective of this study was to compare the efficacy and tolerability of palonosetron and granisetron in a Chinese population
 receiving highly emetogenic cisplatin-based chemotherapy or moderately emetogenic chemotherapy. Patients were stratified by
 chemotherapy with cisplatin (yes/no) and then randomly assigned to receive either palonosetron (0.25&amp;nbsp;mg i.v.) in the first
 cycle followed by granisetron (3&amp;nbsp;mg i.v.) in the second cycle or vice versa. The primary efficacy endpoint was the proportion
 of patients with complete response 0–24&amp;nbsp;h post-chemotherapy administration. The proportions of patients with complete response
 24–120 and 0–120&amp;nbsp;h following chemotherapy were also compared. Of the 144 patients randomized, 36 (25%) received 60–80&amp;nbsp;mg/m2 cisplatin...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154316</comments>
            <pubDate>Tue, 05 Jan 2010 06:51:28 +0100</pubDate>
            <guid isPermaLink="false">3154316</guid>        </item>
        <item>
            <title>Identification of tyrosine phosphoproteins in signaling pathway triggered TGF-a by using functional proteomics technology</title>
            <link>http://www.medworm.com/index.php?rid=3154315&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm561324388h28216%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although several groups had conducted proteomics of nasopharyngeal carcinoma (NPC), little study was involved in phosphoproteomics,
 oncogenic signaling, and cancer research about NPC. Analysis of phosphotyrosine proteins from transforming growth factor alpha
 (TGF-a) triggered phosphotyrosine proteome permitted the identification of novel downstream substrates of the epidermal growth
 factor receptor (EGFR). Using functional proteomics technology based on 2-DE, 2-D western blotting, and mass spectrometry,
 we identified and quantified the tyrosine phosphorylation levels of 16 proteins between control and TGF-a-treated CNE2 human
 NPC cells. Among these proteins, tyrosine phosphorylated levels of ten proteins were increased, and those of six proteins
 were decreased in ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154315</comments>
            <pubDate>Tue, 05 Jan 2010 06:51:28 +0100</pubDate>
            <guid isPermaLink="false">3154315</guid>        </item>
        <item>
            <title>Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era</title>
            <link>http://www.medworm.com/index.php?rid=3154318&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc12957060501x320%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Institutional data are conflicting regarding the prognosis of breast cancer patients with extensive (≥10) axillary lymph node
 (ALN) metastases. We hypothesized that overall survival (OS) and disease specific survival (DSS) improved after the introduction
 of anthracycline-based therapy in 1997. We used the Surveillance, Epidemiology, and End results (SEER) database to identify
 breast cancer patients with ≥10 ALN metastases diagnosed between 1988 and 2004. Patients were categorized according to whether
 they were diagnosed prior to the FDA approval of anthracyclines (pre-anthracycline era, pre-AE) or after approval (post-anthracycline
 era, post-AE). Univariate analyses of OS and DSS were performed using the Kaplan–Meier method and differences assessed via
 the l...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154318</comments>
            <pubDate>Tue, 05 Jan 2010 06:51:24 +0100</pubDate>
            <guid isPermaLink="false">3154318</guid>        </item>
        <item>
            <title>A survey of prognostic value of serum factors in multiple myeloma patients before treatment: macrophage-colony stimulating factor (M-CSF) is a powerful predictor of survival</title>
            <link>http://www.medworm.com/index.php?rid=3136188&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdp78123448425071%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cytokines are involved in the pathogenesis of multiple myeloma (MM) and other cancers. The aim of this study was to evaluate
 a range of cytokines of diverse activity in patients with multiple myeloma for a possible prognostic value. Concentrations
 of the following cytokines and cytokine receptors were measured by ELISA in the sera of 64 untreated MM patients: IL-6, IL-8,
 IL-10, TNFα, sTNF R I and II, sIL-2Rα, IL-1ra, M-CSF, G-CSF, VEGF, and bFGF. Serum levels of sTNF RI, IL-6, and bFGF were
 elevated in over 50% of patients. There was an inverse relationship between sTNF RII, TNFα, IL-1ra, and albumin levels. There
 was no significant relationship between cytokines/cytokine receptors and other serum correlates of myeloma. In a univariate
 survival analysis, β2-mi...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3136188</comments>
            <pubDate>Thu, 31 Dec 2009 06:58:20 +0100</pubDate>
            <guid isPermaLink="false">3136188</guid>        </item>
        <item>
            <title>Experience with sorafenib and the elderly patient</title>
            <link>http://www.medworm.com/index.php?rid=3136189&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F44n12nk426xt0828%2F</link>
            <description>This report describes particular considerations for physicians to be aware of when choosing
 a treatment regimen for their elderly patients with renal cell carcinoma and offers recommendations on how to integrate specific
 management strategies into clinical practice that will optimize the use of sorafenib in the elderly. The strategies focus
 on patient selection, assessment of quality of life, management of adverse events, and appropriate dose modifications. The
 goal of these recommendations is to maximize the clinical benefit of sorafenib in the elderly patient population through appropriate
 use.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9388-4Authors
		Janice P. Dutcher, Montefiore Medical Center-North Division/New York Medical College Department of...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3136189</comments>
            <pubDate>Thu, 31 Dec 2009 06:58:19 +0100</pubDate>
            <guid isPermaLink="false">3136189</guid>        </item>
        <item>
            <title>May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis</title>
            <link>http://www.medworm.com/index.php?rid=3134344&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F661917k8104k6141%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Metaplastic breast carcinoma (MBC) encompasses a heterogeneous group of tumors. Based upon the microarray of MBCs, these tumors
 showed features of basal-like carcinoma and myoepithelial differentiation. However, MBCs entity still remained unclear. So
 we performed a systematic research to explicit metaplastic breast carcinomas further. A panel of ER, PR, HER-2, CK5/6, CK14,
 P63 and EGFR were prepared for detection of MBCs, and fluorescence in situ hybridization for HER-2 gene amplification and ultrastructure observation were also performed. Sensitiveness between CK5/6 and other antibodies in
 diagnosis was analysed, and survival analysis was also carried out. ER, PR and HER-2 were negative. CK5/6 (12/12), CK14 (9/12),
 EGFR (10/12) and P63 (8/12) were positive. FISH f...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3134344</comments>
            <pubDate>Wed, 30 Dec 2009 06:49:07 +0100</pubDate>
            <guid isPermaLink="false">3134344</guid>        </item>
        <item>
            <title>Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells</title>
            <link>http://www.medworm.com/index.php?rid=3134345&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw12p2r11l3383121%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cisplatin (DDP)-based adjuvant chemotherapy is widely used for the treatment of esophageal cancer. However, DDP resistance
 has become more common and thus new approaches are required to be explored. Cisplatin was used to induce autophagy in the
 human esophageal cancer cell line, EC9706 cells, and the effect of autophagy on the survival of EC9706 cells was investigated
 using an autophagy inhibitor 3-MA. Cell viability was measured by CCK8 assay. Apoptosis and cell cycle were detected by flow
 cytometry. Monodansylcadaverine (MDC) was used to detect autophagy. Western blotting assay was used to investigate the molecular
 changes that occurred in the course of treatment. DDP inhibited cell proliferation, induced cell death and cell cycle arrest
 at S phage. Moreover, au...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3134345</comments>
            <pubDate>Wed, 30 Dec 2009 06:49:05 +0100</pubDate>
            <guid isPermaLink="false">3134345</guid>        </item>
        <item>
            <title>FRAT1 expression and its correlation with pathologic grade, proliferation, and apoptosis in human astrocytomas</title>
            <link>http://www.medworm.com/index.php?rid=3134346&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd5k73h4r7l188555%2F</link>
            <description>In conclusion, FRAT1 may be an important factor in the tumorigenesis and progression of astrocytoma, which could
 be used as a potential biomarker for pathological diagnosis of malignancy and a target for biological therapy.
 
	Content Type Journal ArticleCategory original paperDOI 10.1007/s12032-009-9402-xAuthors
		Geng Guo, Fourth Military Medical University Department of Neurosurgery, Xijing Hospital 15# West Chang Le Road 710032 Xi’an Shaanxi Province People’s Republic of ChinaBolin Liu, Fourth Military Medical University Department of Neurosurgery, Xijing Hospital 15# West Chang Le Road 710032 Xi’an Shaanxi Province People’s Republic of ChinaChengliang Zhong, Fourth Military Medical University Department of Health Statistics, Faculty of Preventative Medicine 17# West Chang Le ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3134346</comments>
            <pubDate>Wed, 30 Dec 2009 06:49:01 +0100</pubDate>
            <guid isPermaLink="false">3134346</guid>        </item>
        <item>
            <title>The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study</title>
            <link>http://www.medworm.com/index.php?rid=3134348&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F55726r813p05p927%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;There are no data regarding the late toxicity of trastuzumab (T) administration with radiotherapy (RT). In this experimental
 study, we aimed to asses if concurrent or sequential administration of T has any impact for the development of radiation-induced
 pulmonary fibrosis in rats. Fifty-four female Wistar-albino rats were divided into 6 groups. First group of rats (Group 1;
 concurrent T) had irradiation to whole thoracic region concurrently with T. Second group (Group 2: sequential T–RT) received
 thoracic irradiation, 1&amp;nbsp;week after T. Third group (Group 3: sequential RT–T) had thoracic irradiation first and they had T
 injection 1&amp;nbsp;week after RT. Fourth group (Group 4: T only) had only T application. Fifth group (Group 5: RT) had only RT. The
 last group...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3134348</comments>
            <pubDate>Wed, 30 Dec 2009 06:49:00 +0100</pubDate>
            <guid isPermaLink="false">3134348</guid>        </item>
        <item>
            <title>Discovery of a set of biomarkers of human lung adenocarcinoma through cell-map proteomics and bioinformatics</title>
            <link>http://www.medworm.com/index.php?rid=3134347&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv48171w221357k60%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Carcinogenesis of lung adenocarcinoma remains unclear and very few biomarkers have been accepted for routine clinical use.
 In order to explore the pathogenesis and screen ideal biomarkers, we conducted cell-map proteomics study in human lung adenocarcinoma.
 Homogeneous lung adenocarcinoma cells were purified by laser capture microdissection (LCM). A high performance liquid chromatography
 (HPLC) system was used to separate the total solution proteins. The resulting MS/MS spectra were automatically searched for
 proteins against IPI human protein database using the TurboSEQUEST searching engine. Physico-chemical properties of the identified
 proteins, including molecular weight (MW), isoelectric point (PI), were described based on various proteomics web server and
 sta...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3134347</comments>
            <pubDate>Wed, 30 Dec 2009 06:49:00 +0100</pubDate>
            <guid isPermaLink="false">3134347</guid>        </item>
        <item>
            <title>Treatment of newly diagnosed multiple myeloma: advances in current therapy</title>
            <link>http://www.medworm.com/index.php?rid=3122761&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa1p5kt1821784544%2F</link>
            <description>This article summarizes the recent advances in the treatment of newly diagnosed myeloma and suggests
 a treatment algorithm for approaching newly diagnosed myeloma.
 
	Content Type Journal ArticleCategory original paperDOI 10.1007/s12032-009-9370-1Authors
		Shaji Kumar, Mayo Clinic Rochester MN USA
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3122761</comments>
            <pubDate>Fri, 25 Dec 2009 06:56:21 +0100</pubDate>
            <guid isPermaLink="false">3122761</guid>        </item>
        <item>
            <title>Pulmonary toxicity in patients receiving docetaxel chemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=3122762&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2408144300n472r4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pulmonary toxicity can rarely be seen with cytotoxic agents. We aimed at investigating the pulmonary toxicity of docetaxel
 in patients other than lung carcinoma. Forty patients were investigated prospectively. Spirometry, DLCO and high-resolution
 computed tomography (HRCT) scans were applied to all patients before and 14–21&amp;nbsp;days after completion of docetaxel. We used
 a HRCT scoring system that was based on the previous studies. We have seen no pulmonary symptoms that may reflect pulmonary
 toxicity. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/s), FEV1/FVC
 (%), DLCO/VA (DLCO/L), DLCO/VA (%) (P&amp;nbsp;&amp;lt;&amp;nbsp;0.05), FEF25–75 (L/s), FEF25–75 (%) (P&amp;nbsp;&amp;lt;&amp;nbsp;0.01), DLCO (mL/mmHg/min), DLCO (%) (P&amp;nb...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3122762</comments>
            <pubDate>Fri, 25 Dec 2009 06:56:20 +0100</pubDate>
            <guid isPermaLink="false">3122762</guid>        </item>
        <item>
            <title>An unusual presentation of extramedullary plasmacytoma in testis and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=3122763&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fhu24h316p74835h0%2F</link>
            <description>We report a 73-year-old
 man with multiple myeloma presented with testicular plasmacytoma. He complained of left leg pain and scrotal swelling. Ultrasonography
 revealed testicular masses. Pathologic examination of the orchiectomy specimen showed plasmocytoma with kappa expression.
 Multiple lytic bone lesions were seen in bone survey scans, serum immunoelectrophoresis and bone marrow aspiration aided to
 the diagnosis of multiple myeloma. He received chemotherapy, melphalan and prednisolone, and palliative radiotherapy. He succumbed
 to disease after 8&amp;nbsp;months.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9390-xAuthors
		H. Mehmet Turk, Gaziantep University Department of Clinical Oncology, Faculty of Medicine Gaziantep 27310 TurkeySeref Komurcu, GATA Fa...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3122763</comments>
            <pubDate>Fri, 25 Dec 2009 06:56:18 +0100</pubDate>
            <guid isPermaLink="false">3122763</guid>        </item>
        <item>
            <title>Association between EGF promoter polymorphisms and cancer risk: a meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=3122764&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa80g082003884603%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 EGF promoter polymorphisms are observed to modulate EGF levels and thought to have effect on susceptibility to various carcinomas
 but the results are inconsistent. In this meta-analysis, we assessed published studies of the association between three EGF polymorphisms and cancer risk from 21 studies with 14,609 subjects for EGF G61A, from two studies with 2,535 subjects for G-1380A and A-1744G, respectively. For EGF G61A, the contrast of homozygote (OR&amp;nbsp;=&amp;nbsp;0.80, 95% CI&amp;nbsp;=&amp;nbsp;0.65–0.98), allele (OR&amp;nbsp;=&amp;nbsp;0.90, 95% CI&amp;nbsp;=&amp;nbsp;0.81–0.99) and dominant model
 (OR&amp;nbsp;=&amp;nbsp;0.86, 95% CI&amp;nbsp;=&amp;nbsp;0.74–0.99) produced significant association among 21 studies with relatively large heterogeneity (P
 heterogeneity&amp;nbsp;&amp;lt;&amp;nbsp;0.001). Through ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3122764</comments>
            <pubDate>Thu, 24 Dec 2009 19:49:32 +0100</pubDate>
            <guid isPermaLink="false">3122764</guid>        </item>
        <item>
            <title>Clinical characteristics and outcomes of women with stage IV endometrial cancer</title>
            <link>http://www.medworm.com/index.php?rid=3109020&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq6l4908l61013v14%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Treatment strategies for patients with stage IV endometrial cancer (EC) remain controversial. Some studies have suggested
 that optimal cytoreduction improves survival. We retrospectively analyzed the clinical characteristics and outcomes of 41
 women with stage IV EC. The results of preoperative cytologic evaluation and biopsy of the endometrium were reviewed by a
 single pathologist for patients in whom stage IV EC was diagnosed preoperatively. Of the 41 patients with stage IV EC (median
 age, 62&amp;nbsp;years), 31 had surgical stage IV disease and 10 had clinical stage IV disease. Twenty-eight patients were diagnosed
 of stage IV EC before surgery or without surgery. Progression-free survival and overall survival were 10.4 and 21.3&amp;nbsp;months,
 respectively. On univari...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3109020</comments>
            <pubDate>Sat, 19 Dec 2009 06:52:17 +0100</pubDate>
            <guid isPermaLink="false">3109020</guid>        </item>
        <item>
            <title>The association of serum adiponectin levels with histopathological variables in gastric cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=3105974&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff6k1062777t5t338%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Adiponectin is a peptide hormone secreted from the adipose tissue, affecting the proliferation and insulin sensitivity in
 different cell types. The levels of adiponectin have been found to be decreased in hyperinsulinemia and insulin resistant
 states, such as obesity. The previous studies have suggested that plasma adiponectin levels are decreased in patients with
 endometrial and breast cancer. In our study, the relationship among serum adiponectin levels, demographic features and histopathological
 variables was evaluated in gastric cancer patients. Forty consecutive patients with gastric cancer who underwent gastrectomy
 with standard lymph node dissection were included and 43 healthy controls were included in this study. The serum levels of
 glucose, insulin, C-pe...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3105974</comments>
            <pubDate>Wed, 16 Dec 2009 07:04:59 +0100</pubDate>
            <guid isPermaLink="false">3105974</guid>        </item>
        <item>
            <title>Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia</title>
            <link>http://www.medworm.com/index.php?rid=3105976&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnv30232rq72w5054%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The clinical course of CLL is highly variable, and survival from the time of diagnosis of CLL can range from months to decades.
 Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic informations.
 Few reports deal with the sCD138 levels and bad prognostic factors in patients with CLL, and contrasting data are reported
 in literature. In our study, we evaluated the serum level of sCD138 in patients with B-CLL and its relationship with other prognostic markers. There was a significant association between advanced Rai stage and
 serum sCD138 levels in CLL subjects. Patients with Rai stage III-IV had significantly higher levels of sCD138 with respect
 to controls (48.85&amp;nbsp;±&amp;nbsp;34&amp;nbsp;ng/ml vs. 31.1&amp;nbsp;...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3105976</comments>
            <pubDate>Wed, 16 Dec 2009 07:04:58 +0100</pubDate>
            <guid isPermaLink="false">3105976</guid>        </item>
        <item>
            <title>Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan</title>
            <link>http://www.medworm.com/index.php?rid=3105975&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxn16u53630r058k7%2F</link>
            <description>This study was carried out to find whether propolis preparations and related flavonoids (quercetin,
 naringin) might enhance irinotecan-induced cytotoxicity to tumor cells in mice bearing Ehrlich ascites tumors (EAT) while
 protecting normal blood, liver, and kidney cells. The preparation of propolis and their flavonoids were given to mice intraperitoneally
 at a dose of 100&amp;nbsp;mg&amp;nbsp;kg−1 body weight for three consecutive days before the ip injection of EAT cells (2&amp;nbsp;×&amp;nbsp;106). Irinotecan was administered ip at dose of 50&amp;nbsp;mg&amp;nbsp;kg−1 on days 3, 4, and 5 after tumor cell inoculation. The combination treatment resulted in substantial inhibition of the growth
 of EAT cells as well as treatment with quercetin or irinotecan alone, whereas other treatment by itself showed li...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3105975</comments>
            <pubDate>Wed, 16 Dec 2009 07:04:58 +0100</pubDate>
            <guid isPermaLink="false">3105975</guid>        </item>
        <item>
            <title>A mimic of phosphorylated prolactin inhibits human breast cancer cell proliferation via upregulation of p21 waf1</title>
            <link>http://www.medworm.com/index.php?rid=3097735&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgn1lx776uq317r61%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A mimic of phosphorylated prolactin (S179D PRL) inhibits mouse normal mammary HC11 cell proliferation through the upregulation
 of the vitamin D receptor (VDR) and p21. Here, we investigated whether S179D PRL also inhibited growth of human breast cancer
 MCF7 cells via VDR and p21. Western blots showed that S179D PRL upregulated VDR and p21 after the cells were incubated with
 S179D PRL for 3&amp;nbsp;days. These effects were blocked by the MAP kinase blocker PD98059 (25&amp;nbsp;μM), indicating that MAPK plays a role
 in VDR and p21 upregulation. To confirm whether VDR contributes to p21 upregulation, we used two constructs that express luciferase.
 One (p21 VDRE Luc) has the vitamin D response element (VDRE) in the p21 promoter region; the other (p21 NO-VDRE Luc) does
 not. ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3097735</comments>
            <pubDate>Tue, 15 Dec 2009 07:12:39 +0100</pubDate>
            <guid isPermaLink="false">3097735</guid>        </item>
        <item>
            <title>Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence</title>
            <link>http://www.medworm.com/index.php?rid=3085903&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc83x12l202202185%2F</link>
            <description>This study included 100 patients diagnosed with bladder cancer,
 93 patients with benign urological disorders and 47 healthy volunteers. The urine supernatant was used for determination of
 fibronectin by ELISA, while urine sediment was used for cytology and detection of mutant p53 by PCR-SSCP followed by DNA sequencing.
 The sensitivity and specificity were 59% and 91.4% for VUC, 82% and 84.3% for fibronectin, and 37% and 100% for mutant p53;
 combination of the three parameters increased sensitivity to 95% but specificity was only 78.6%. A significant association
 was observed between disease recurrence and mutant p53, stage and lymph node involvement. Our results indicate that fibronectin
 had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, m...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3085903</comments>
            <pubDate>Fri, 11 Dec 2009 06:54:54 +0100</pubDate>
            <guid isPermaLink="false">3085903</guid>        </item>
        <item>
            <title>Future directions in immunomodulatory therapy</title>
            <link>http://www.medworm.com/index.php?rid=3085905&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb056w325575t1816%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The role of immunomodulatory-based therapy with thalidomide or lenalidomide is clearly established in the management of patients
 with myeloma in all phases of their disease. Recent preclinical and clinical works have demonstrated that in addition to combination
 therapy with dexamethasone, there is significant activity when combined with the proteasome inhibitor bortezomib. More recent
 clinical studies have also demonstrated significant activity when combined with akt inhibitors, HDAC inhibitors, and even
 monoclonal antibodies. Further clinical development of immunomodulatory agents should continue to be based on preclinical
 rationale, which has resulted in a number of promising and clinically active combinations.
 
	Content Type Journal ArticleCategory Original Pap...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3085905</comments>
            <pubDate>Fri, 11 Dec 2009 06:54:53 +0100</pubDate>
            <guid isPermaLink="false">3085905</guid>        </item>
        <item>
            <title>Notch1 expression correlates with tumor differentiation status in ovarian carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3085904&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk5225545074h6276%2F</link>
            <description>In this study, we detected the expression of Notch1 in ovarian tissues and human
 ovarian cancer cell lines. We also analyzed the expression of Notch1 and its relationship with differentiation status and
 FIGO (Federation International of Gynecology and Obstetrics) stage in ovarian cancer tissues. Immunohistochemistry, real-time
 polymerase chain reaction and Western blot were used to detect the expression of Notch1 in 109 ovarian cancer tissues, 65
 patient-matched opposite side normal ovarian tissues and 48 normal ovarian tissues, together with A2780, HO-8910 and IOSE
 144 cell lines. Our results showed that the expression of Notch1 in ovarian cancer tissues was higher than that in matched
 normal tissues and normal tissues, Notch1 is highly expressed in ovarian cancer cells A2780 and HO...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3085904</comments>
            <pubDate>Fri, 11 Dec 2009 06:54:53 +0100</pubDate>
            <guid isPermaLink="false">3085904</guid>        </item>
        <item>
            <title>Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer</title>
            <link>http://www.medworm.com/index.php?rid=3085907&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl54634n233363237%2F</link>
            <description>In conclusion, sorcin might play an important role in the resistibility to gemcitabine,
 and it could also be a novel candidate biomarker for predicting the response of NSCLC patients to gemcitabine treatment.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9379-5Authors
		Yiqing Qu, Shandong University Department of Respiratory Medicine, Qilu Hospital 250012 Jinan ChinaYie Yang, Shandong Provincial Qianfoshan Hospital Clinical Laboratory 250014 Jinan ChinaBaoyi Liu, Shandong University Department of Respiratory Medicine, Qilu Hospital 250012 Jinan ChinaWei Xiao, Shandong University Department of Respiratory Medicine, Qilu Hospital 250012 Jinan China
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3085907</comments>
            <pubDate>Thu, 10 Dec 2009 15:24:29 +0100</pubDate>
            <guid isPermaLink="false">3085907</guid>        </item>
        <item>
            <title>Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3085906&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc5271555v5027g60%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s12032-009-9378-6Authors
		Erkan Dogan, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeySercan Aksoy, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyCagatay Arslan, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyDidem S. Dede, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyKadri Altundag, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara Turkey
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3085906</comments>
            <pubDate>Thu, 10 Dec 2009 15:24:29 +0100</pubDate>
            <guid isPermaLink="false">3085906</guid>        </item>
        <item>
            <title>TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=3085908&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F425638134g217271%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Transforming growth factor β (TGF-β) is a cytokine. The TGF-β signaling pathway plays an important role in controlling cell
 proliferation and differentiation involved in colorectal carcinogenesis. In mammalian cells, TGFB1 is the most abundant subtype
 of TGF-β. The 509 C/T polymorphism in TGFB1 has been implicated in colorectal cancer risk. However, published data remain
 conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 994 cases and 2,335 controls from
 five published case–control studies was performed. Overall, significantly increased colorectal cancer risks were found for
 CC versus TT (OR&amp;nbsp;=&amp;nbsp;1.62; 95% CI: 1.30–2.02; P
 heterogeneity&amp;nbsp;=&amp;nbsp;0.118), TC&amp;nbsp;+&amp;nbsp;CC versus TT (OR&amp;nbsp;=&amp;nbsp;1.30; 95% CI...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3085908</comments>
            <pubDate>Thu, 10 Dec 2009 15:24:28 +0100</pubDate>
            <guid isPermaLink="false">3085908</guid>        </item>
        <item>
            <title>Liver transplantation for primary hepatic leiomyosarcoma: a case report and review of the literatures</title>
            <link>http://www.medworm.com/index.php?rid=3080366&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd82828904p73m592%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Primary hepatic leiomyosarcoma (PHL), a malignant mesenchymal tumor of myogenic origin, is exceedingly rare. Patients may
 be afflicted with a wide spectrum of nonspecific symptoms, and most of the laboratory data are unhelpful to diagnosis. Here,
 we report a 44-year-old woman with anorexia and right upper quadrant pain who was diagnosed as having malignant hepatic tumor
 within the Milan criteria and treated by orthotopic liver transplantation (OLT), the pathologic diagnosis of PHL was made
 by postoperative immunohistochemical study. She underwent six courses of intravenous chemotherapy and enjoyed a 14-month tumor
 recurrence-free survival until the lymph node metastasis was detected, then we switched the tacrolimus to sirolimus and the
 patient survived for 20&amp;nbsp...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3080366</comments>
            <pubDate>Wed, 09 Dec 2009 06:51:15 +0100</pubDate>
            <guid isPermaLink="false">3080366</guid>        </item>
        <item>
            <title>Port central venous catheters–associated bloodstream infection during outpatient-based chemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=3064181&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq7g6877033l8w07x%2F</link>
            <description>We describe
 a large outbreak of CVCs-associated Klebsiella oxytoca bloodstream infection, occurring in an oncology chemotherapy outpatient unit of northern Greece between October 2006 and
 May 2007. The outbreak involved approximately 10% of the patients with CVCs who were receiving home-based chemotherapy, and
 it represents the second larger outbreak of CVCs-associated BSIs due to Klebsiella oxytoca in oncology outpatient centers. We retrospectively analyzed the chain of investigations and prophylactic/diagnostic measures
 taken to eradicate the infection: (1) patients’ chart audit, (2) estimation of the infection among asymptomatic patients,
 (3) implementation of the level of awareness of medical and paramedical personnel, (4) collection of samples from environment,
 medications and...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064181</comments>
            <pubDate>Sat, 05 Dec 2009 09:00:00 +0100</pubDate>
            <guid isPermaLink="false">3064181</guid>        </item>
        <item>
            <title>Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study</title>
            <link>http://www.medworm.com/index.php?rid=3064183&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F82221l5tm65522n6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This pilot study was undertaken to assess the effect of weekly docetaxel, cisplatin and fluorouracil (DCF) as a preoperative
 treatment for gastric cancer with multiple synchronous hepatic metastases. Gastric cancer patients with synchronous multiple
 liver metastasis were first given preoperative chemotherapy consisting of two courses (each course consisted of 6-week administration
 and 2-week withdrawal) of weekly DCF regimen. Following the operation, postoperative chemotherapy and hepatic arterial infusion
 (HAI) treatment were performed as required. Eight patients completed two courses of preoperative chemotherapy with weekly
 DCF regimen. No toxicity of grade 3 or more was observed during the course of chemotherapy. The response rate was 100% according
 to the RECI...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064183</comments>
            <pubDate>Sat, 05 Dec 2009 08:59:59 +0100</pubDate>
            <guid isPermaLink="false">3064183</guid>        </item>
        <item>
            <title>Decreased expression of KLF6 and its significance in gastric carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3064182&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg382537824276613%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To study the expression of the Krüppel-like transcription factor 6 (KLF6) in human gastric carcinoma and normal gastric mucosa
 tissues, and to explore the role of KLF6 in the carcinogenesis and tumor progression and its clinical significance. Expression
 of KLF6, P21WAF1 and PCNA was investigated by immunohistochemistry for 69 surgically resected gastric carcinoma tissues and corresponding
 normal gastric mucosa tissues, respectively. The correlations of KLF6 expression with clinicopathological characteristics,
 P21WAF1 and PCNA were examined. Positive-expression of KLF6 was 64 out of 69 cases (92.8%) in normal gastric mucosa and only 23 cases
 (33.3%) in gastric carcinoma. Expression of KLF6 in the gastric carcinoma was remarkably lower than normal gastric mucosa.
 D...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064182</comments>
            <pubDate>Sat, 05 Dec 2009 08:59:59 +0100</pubDate>
            <guid isPermaLink="false">3064182</guid>        </item>
        <item>
            <title>Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3064184&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx51547612844g142%2F</link>
            <description>Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9371-0Authors
		Giuseppe Procopio, Fondazione Istituto Nazionale dei Tumori Medical Oncology, Unit 2 Milan ItalyElena Verzoni, Fondazione Istituto Nazionale dei Tumori Medical Oncology, Unit 2 Milan ItalyEmilio Bajetta, Fondazione Istituto Nazionale dei Tumori Medical Oncology, Unit 2 Milan Italy
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064184</comments>
            <pubDate>Wed, 02 Dec 2009 08:39:50 +0100</pubDate>
            <guid isPermaLink="false">3064184</guid>        </item>
        <item>
            <title>Polycomb group protein Bmi1 expression in colon cancers predicts the survival</title>
            <link>http://www.medworm.com/index.php?rid=3064185&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm182822976271v74%2F</link>
            <description>We examined the expression of the Bmi1 in colon cancer and its relevance to other characteristics, especially the 5-year survival
 of colon cancer. The expression of Bmi1 was examined in colorectal carcinoma (n&amp;nbsp;=&amp;nbsp;98) by using real-time polymerase chain reaction. Expression was correlated with clinicopathologic variables, 5-year overall
 survival (OS) rates. We for the first time found that high expression of Bmi1 was significantly associated with poor survival.
 Fourfold Table Chi-square Test analysis revealed that Bmi1 expression was closely related to TNM stage and histologic grade,
 while not relevant to age. In summary, the high expression of polycomb-group protein Bmi1 is an essential and important predictor
 of colorectal cancer prognosis.
 
	Content Type Journal ArticleCat...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064185</comments>
            <pubDate>Tue, 01 Dec 2009 21:05:17 +0100</pubDate>
            <guid isPermaLink="false">3064185</guid>        </item>
        <item>
            <title>Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy</title>
            <link>http://www.medworm.com/index.php?rid=3053750&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F332614151g512q4j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Due to the ineffective conventional treatment for hepatocellular carcinoma (HCC), the nonviral gene delivery system has been
 proved to be an attractive alternative to HCC therapy. In this work, we have developed a kind of new self-assembled nanoparticles,
 which were named as amino-modified silica nanoparticles (AMSNs). Scanning electron microscopy and zeta potential results demonstrated
 that AMSNs had a diameter of 20–30&amp;nbsp;nm and positive surface charges of +11.3&amp;nbsp;mV, respectively. The AMSNs could bind DNA strongly
 and protect DNA from degradation, which was confirmed by DNA-binding assay and serum protection assay. Furthermore, AMSNs
 could transfer foreign DNA into targeted cells with high transfection efficiency and little cytotoxicity. Combined with the...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3053750</comments>
            <pubDate>Tue, 01 Dec 2009 08:43:38 +0100</pubDate>
            <guid isPermaLink="false">3053750</guid>        </item>
        <item>
            <title>The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer</title>
            <link>http://www.medworm.com/index.php?rid=3053751&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F285831v2k15u7j47%2F</link>
            <description>This study investigated the effect of MMR status on the treatment outcomes for CAPOX and FOLFOX as first-line combination
 chemotherapy in recurrent or metastatic colon cancer. We analyzed 171 patients who had been treated with CAPOX or FOLFOX as
 first-line combination chemotherapy in recurrent or metastatic colon adenocarcinoma between February 2004 and July 2008. Tumor
 expression of the MMR proteins, MLH1 and MSH2, was detected by immunohistochemistry (IHC) in surgically resected tumor specimens.
 The microsatellite instability (MSI) was analyzed by polymerase chain reaction (PCR) amplification, using fluorescent dye-labeled
 primers specific to microsatellite loci. Tumors with MMR defect were defined as those demonstrating a loss of MMR protein
 expression (MMR-D) and/or a microsatell...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3053751</comments>
            <pubDate>Tue, 01 Dec 2009 08:43:36 +0100</pubDate>
            <guid isPermaLink="false">3053751</guid>        </item>
        <item>
            <title>Antitumor effect of mSurvivinThr34 → Ala in murine colon carcinoma when administered intravenously</title>
            <link>http://www.medworm.com/index.php?rid=3097736&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9330475267455726%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colorectal cancer is one of the most common cancers. Survivin is strongly immunogenic in a fraction of colorectal cancer patients.
 The present study was designed to determine whether full-length mouse Survivin dominant-negative mutant SurvivinT34A has the
 antitumor activity in a murine colon carcinoma model. The complex of cationic liposome (DOTAP/Chol) to plasmid pORF9—mSurvivin
 T34A was administered intravenously in a mouse subcutaneous (S. C.) CT 26 tumor model. Apoptotic cells and anti-angiogenesis
 were evaluated by fluorescent in situ TUNEL assay and by immunohistochemistry with an antibody reactive to CD31, respectively.
 A 4&amp;nbsp;h 51Cr release assay was performed to determine Survivin-specific cytotoxicity. The adoptive transfer of CD8+ or CD4+ T-lymphocyt...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3097736</comments>
            <pubDate>Tue, 01 Dec 2009 08:43:34 +0100</pubDate>
            <guid isPermaLink="false">3097736</guid>        </item>
        <item>
            <title>Multimodality management for 145 cases of Merkel cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=3053753&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq028p41452571p71%2F</link>
            <description>In conclusion, recurrence should be treated with multimodalities. Our experience of long-term survivors
 after treatment of recurrence is encouraging.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9369-7Authors
		Patricia Tai, University of Saskatchewan Department of Radiation Oncology, Allan Blair Cancer Center 4101 Dewdney Avenue Regina SK S4T 7T1 CanadaEdward Yu, University of Western Ontario London ON CanadaAvi Assouline, Centre hospitalier Universitaire d’Amiens Amiens FranceJi Dong Lian, Windsor Cancer Center Windsor ON CanadaKurian Joseph, University of Alberta Cross Cancer Institute Edmonton AB CanadaThomas Miale, University of Saskatchewan Department of Radiation Oncology, Allan Blair Cancer Center 4101 Dewdney Avenue Regina SK S4T 7T1 CanadaClaude...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3053753</comments>
            <pubDate>Tue, 01 Dec 2009 08:43:34 +0100</pubDate>
            <guid isPermaLink="false">3053753</guid>        </item>
        <item>
            <title>Antitumor effect of mSurvivinThr34 → Ala in murine colon carcinoma when administered intravenously</title>
            <link>http://www.medworm.com/index.php?rid=3053752&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9330475267455726%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colorectal cancer is one of the most common cancers. Survivin is strongly immunogenic in a fraction of colorectal cancer patients.
 The present study was designed to determine whether full-length mouse Survivin dominant-negative mutant SurvivinT34A has the
 antitumor activity in a murine colon carcinoma model. The complex of cationic liposome (DOTAP/Chol) to plasmid pORF9—mSurvivin
 T34A was administered intravenously in a mouse subcutaneous (S. C.) CT 26 tumor model. Apoptotic cells and anti-angiogenesis
 were evaluated by fluorescent in situ TUNEL assay and by immunohistochemistry with an antibody reactive to CD31, respectively.
 A 4&amp;nbsp;h 51Cr release assay was performed to determine Survivin-specific cytotoxicity. The adoptive transfer of CD8+ or CD4+ T-lymphocyt...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3053752</comments>
            <pubDate>Tue, 01 Dec 2009 08:43:34 +0100</pubDate>
            <guid isPermaLink="false">3053752</guid>        </item>
        <item>
            <title>Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells</title>
            <link>http://www.medworm.com/index.php?rid=3053754&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F87107053m0571gj7%2F</link>
            <description>We examined
 the expression of HBx gene after RNA interference by semi-quantitative RT-PCR and assessed the effect of HBx knocked down
 on cell growth by proliferation assay using kit-8 (CCK8). As well as, we analyzed cell cycle distribution by flowcytometry
 and examined cell apoptosis using TUNEL assay. The HBx mRNA expression level is reduced, and cells growth was significantly
 stopped in 21543 cell lines. Cells with HBx knockdown were more sensitive to 5-fluorouracil/cisplatin. RNA interfering HBx
 induced an obvious time and dose-dependent inhibitory in comparison with the control cells. Meanwhile, RNA interferenced targeting
 HBx, in combination with chemotherapy can effectively induce apoptosis in hepatocellular carcinoma cells and restricts cell
 proliferation.
 
	Content Type Jou...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3053754</comments>
            <pubDate>Tue, 01 Dec 2009 08:43:33 +0100</pubDate>
            <guid isPermaLink="false">3053754</guid>        </item>
        <item>
            <title>Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil</title>
            <link>http://www.medworm.com/index.php?rid=3040819&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm185274512t40464%2F</link>
            <description>In conclusion, hyperleukocytosis confers a poorer prognosis in patients with AML.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9367-9Authors
		L. C. O. Oliveira, University of Sao Paulo Medical School of Ribeirao Preto Rua Tenente Catão Roxo, 2501 Ribeirão Preto SP 14051-140 BrazilL. G. M. Romano, University of Sao Paulo Medical School of Ribeirao Preto Rua Tenente Catão Roxo, 2501 Ribeirão Preto SP 14051-140 BrazilB. P. A. Prado-Junior, University of Sao Paulo Blood Center of Ribeirao Preto Ribeirao Preto BrazilD. T. Covas, University of Sao Paulo Medical School of Ribeirao Preto Rua Tenente Catão Roxo, 2501 Ribeirão Preto SP 14051-140 BrazilE. M. Rego, University of Sao Paulo Medical School of Ribeirao Preto Rua Tenente Catão Roxo, 2501 Ribeirão Pr...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3040819</comments>
            <pubDate>Wed, 25 Nov 2009 17:03:38 +0100</pubDate>
            <guid isPermaLink="false">3040819</guid>        </item>
        <item>
            <title>Other malignancies in patients with breast cancer: a single institute experience</title>
            <link>http://www.medworm.com/index.php?rid=3031678&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F17j40521w9314tr2%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s12032-009-9368-8Authors
		Erkan Dogan, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeySercan Aksoy, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyOmer Dizdar, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyDidem S. Dede, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyCagatay Arslan, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyYavuz Ozisik, Hacettepe University Institute of Oncology Department of Medical Oncology Sihhiye 06100 Ankara TurkeyKadri Altun...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3031678</comments>
            <pubDate>Tue, 24 Nov 2009 07:16:14 +0100</pubDate>
            <guid isPermaLink="false">3031678</guid>        </item>
        <item>
            <title>Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer</title>
            <link>http://www.medworm.com/index.php?rid=3031680&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F02w34567258l2127%2F</link>
            <description>This study included 51 patients with EOC, 27
 patients with benign ovarian lesions and 29 healthy volunteers. Serum CA 125 was determined by microparticle enzyme immunoassay,
 while serum MMP-7, CCL18 and CCL11 were measured using enzyme-linked immunosorbent assay. The sensitivity and specificity
 were 86.3% and 92.9% for CA 125, 80.4% and 87.5% for MMP-7, 84.3% and 91.1% for CCL18 and, 68.6% and 62.5% for CCL11. Combination
 of CA 125, MMP-7, CCL18 and CCL11 gave a promising sensitivity of 100%, but specificity was decreased to 60.7%. The combined
 use of serum CA 125, MMP-7, CCL18 and CCL11 effectively detected early stages EOC with high sensitivity of 94.4%. Our data
 indicate that serum MMP-7, CCL18 and CCL11, in combination with CA 125 could be useful in diagnosis of EOC.
 
	Content T...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3031680</comments>
            <pubDate>Tue, 24 Nov 2009 07:16:13 +0100</pubDate>
            <guid isPermaLink="false">3031680</guid>        </item>
        <item>
            <title>A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients</title>
            <link>http://www.medworm.com/index.php?rid=3031679&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F03428l35333h4w42%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Castleman’s disease (CD) is a rare disorder characterized by non-cancerous tumor growth that may develop in the lymph node
 tissue at a single site or throughout the body (Castleman et al. in Cancer 9:822–830, 1956). It involves hyperproliferation
 of specific B cells that produce the cytokine IL-6. This disorder is often undiagnosed or misdiagnosed. For this reason, only
 very few patients have been reported, and little information is available in the literature. In hopes of providing a better
 understanding of this rare disease, this report examines 52 patients with Unicentric Castleman’s disease (UCD) and Multicentric
 Castleman’s disease (MCD) treated from 1999–2008 at a single institution. Fifty-two patients with CD, along with their histological
 diagnos...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3031679</comments>
            <pubDate>Tue, 24 Nov 2009 07:16:13 +0100</pubDate>
            <guid isPermaLink="false">3031679</guid>        </item>
        <item>
            <title>Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR</title>
            <link>http://www.medworm.com/index.php?rid=3031681&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff32308527242665n%2F</link>
            <description>This study evaluates the inhibition of in vitro propagating LNCaP
 cells employing mono- and bispecific oligos directed against bcl-2 [the second bispecific binding site was directed against
 the epidermal growth factor receptor (EGFR)]. Employing RT-PCR, the expression of non-targeted proteins encoded by mRNA for
 prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA) were subsequently evaluated. When LNCaP prostate
 tumor cells were incubated with bispecific oligos (directed against bcl-2 and EGFR) and compared to lipofectin-containing
 controls significant growth inhibition resulted. In subsequent experiments, the levels of mRNA encoding PSMA were unexpectedly
 found to be elevated following treatment with the bispecific oligos but not with the monospecific direct...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3031681</comments>
            <pubDate>Tue, 24 Nov 2009 07:16:12 +0100</pubDate>
            <guid isPermaLink="false">3031681</guid>        </item>
        <item>
            <title>mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis</title>
            <link>http://www.medworm.com/index.php?rid=3019979&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fkq1220077gr46135%2F</link>
            <description>This study investigated
 for the first time the correlation between the mTOR/p70S6K signal transduction pathway in human osteosarcoma and patients’
 prognosis. The expression patterns of mTOR and p70S6K in paraffin-embedded specimens gathered from 65 patients with primary
 osteosarcoma were detected by the method of immunohistochemistry using antibodies against mTOR and p70S6K. Kaplan–Meier survival
 and Cox regression analyses were performed to evaluate the prognosis of patients. Immunostaining revealed that the mTOR/p70S6K
 signal transduction pathway is activated in human osteosarcoma. Additionally, positive expression of mTOR and p70S6K proteins
 was significantly correlated with surgical stage, metastasis pattern and percentage of dead cells of osteosarcoma. Moreover,
 in univaria...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3019979</comments>
            <pubDate>Sat, 21 Nov 2009 08:56:20 +0100</pubDate>
            <guid isPermaLink="false">3019979</guid>        </item>
        <item>
            <title>Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)</title>
            <link>http://www.medworm.com/index.php?rid=3016045&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F38w15112832t2128%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In this retrospective study, we investigated the incidence of esophagorespiratory fistula (ERF) in esophageal squamous cell
 carcinomas, clinical characteristics and outcomes of esophageal cancer patient with ERF, and effective therapeutic options.
 From 1998 to 2007, 1,095 patients with squamous cell carcinomas of the esophagus were treated at Samsung Medical Center. A
 comprehensive retrospective review of all these patients with clinical data of ERF was performed. The incidence of ERF in
 patients with esophageal cancer was 4.7% (52/1095). Comparing with the patients without ERF, the patients with ERF presented
 with a more advanced stage of disease, more frequent involvement of upper-mid thoracic esophagus, a longer segment of the
 tumor, and more initial airway inv...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016045</comments>
            <pubDate>Thu, 19 Nov 2009 07:25:46 +0100</pubDate>
            <guid isPermaLink="false">3016045</guid>        </item>
        <item>
            <title>Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor</title>
            <link>http://www.medworm.com/index.php?rid=3016046&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2235888r497v8932%2F</link>
            <description>In this study, we first analyze the role of HDGF in colorectal carcinoma (CRC) progression by immunohistochemistry. Then we
 used small interference RNA (HDGF-siRNA) to block HDGF and assessed its effect on inducing apoptosis of CRC loVo cells. Apoptosis
 was detected using flow cytometry (FCM), DNA ladder analysis, and Hoechst 33258 staining. In addition, the expression levels
 of some apoptosis-related proteins were examined by western blot. The result showed that HDGF expression gradually increased
 in the colorectal carcinogenesis process. Further studies demonstrated that knock-down of HDGF can down-regulate the survivin,
 activate the mitochondrial pathway, and induce apoptosis in loVo cells. These findings suggest that HDGF is involved in colorectal
 carcinogenesis process. Further ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016046</comments>
            <pubDate>Thu, 19 Nov 2009 07:25:44 +0100</pubDate>
            <guid isPermaLink="false">3016046</guid>        </item>
        <item>
            <title>Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression</title>
            <link>http://www.medworm.com/index.php?rid=3016047&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh560q1612n38mw76%2F</link>
            <description>In conclusion, serum BMP-2 is associated with progression from early localized gastric cancer to locally advanced
 gastric cancer.
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s12032-009-9358-xAuthors
		Yong Park, Korea University Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine Guro Hospital, 80 Guro-Dong, Guro-Gu Seoul 152-703 KoreaMyoung Hee Kang, Korea University Graduate School of Medicine Seoul KoreaHee Yeon Seo, Korea University Division of Hematology/Oncology, Department of Internal Medicine, College of Medicine Guro Hospital, 80 Guro-Dong, Guro-Gu Seoul 152-703 KoreaJoong Min Park, Chung-Ang University Department of Surgery, College of Medicine Seoul KoreaChul Won Choi, Korea University Division of Hematology/Oncology, Depa...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3016047</comments>
            <pubDate>Thu, 19 Nov 2009 07:25:43 +0100</pubDate>
            <guid isPermaLink="false">3016047</guid>        </item>
        <item>
            <title>Pathologic complete response of a solitary melanoma brain metastasis after local ablative radiation therapy: case report</title>
            <link>http://www.medworm.com/index.php?rid=3009610&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F321x4155hx427m53%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A 73-year-old female with malignant melanoma metastatic to her left frontal lobe status post-gross total resection of the
 metastasis, whole brain radiotherapy, and Gamma Knife-based stereotactic radiosurgery for local recurrence presented with
 an area of increasing enhancement on follow-up magnetic resonance imaging (MRI) and hypermetabolic lesions on 18-fluorodeoxyglucose
 positron emission tomography/computerized tomography (18FDG PET/CT) of the brain suspicious for tumor recurrence. Surgical resection of the lesion was performed showing radiation
 necrosis with no evidence of tumor. The patient was alive 1&amp;nbsp;year after her second craniotomy. This case illustrates that despite
 being perceived as a radioresistant histology, complete local eradication of melanoma ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3009610</comments>
            <pubDate>Wed, 18 Nov 2009 09:36:34 +0100</pubDate>
            <guid isPermaLink="false">3009610</guid>        </item>
        <item>
            <title>Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma</title>
            <link>http://www.medworm.com/index.php?rid=3009612&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn643g4r2k211831x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of the study was to investigate whether the presence of matrix metalloproteinase-2 (MMP-2) and its inducer, extracellular
 matrix metalloproteinase inducer (EMMPRIN), in primary cutaneous malignant melanoma (PCMM) might help to predict patient prognosis.
 Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections of PCMM from 150 patients. Association
 of clinical variables (gender, age, tumor location, thickness, Clark level and AJCC stage) with EMMPRIN and MMP-2 expression
 were analyzed by Fisher’s exact test. Survival rates were subsequently estimated using the Kaplan–Meier method and compared
 using the log-rank test. The expression of EMMPRIN and MMP-2 was detected in 117/150 (78.0%) and 115/150 (76.7%) of patients
 with P...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3009612</comments>
            <pubDate>Wed, 18 Nov 2009 03:47:33 +0100</pubDate>
            <guid isPermaLink="false">3009612</guid>        </item>
        <item>
            <title>Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells</title>
            <link>http://www.medworm.com/index.php?rid=3009611&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn506633g752w57n2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Antiapoptosis and invasion are the causes for the failure of conventional radiotherapy and chemotherapy in human renal carcinomas.
 Osteopontin (OPN), a ligand for vß3 integrin and CD44 receptors, is a phosphorylated glycoprotein with diverse functions including
 tumorigenesis and tumor cell metastasis. Recently, OPN has been detected in human renal carcinomas and assessed as a potential
 prognostic marker of renal carcinomas. However, the function and mechanism of OPN in renal carcinomas remain unknown. In this
 study, we used OPN siRNA to silence the expression of OPN in renal carcinoma Caki-1 cells. Silent effect showed that sequence-specific
 siRNA targeting OPN suppressed OPN mRNA expression by 81% and OPN protein level by 91% in vitro. The apoptosis ability was
 ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3009611</comments>
            <pubDate>Wed, 18 Nov 2009 03:47:33 +0100</pubDate>
            <guid isPermaLink="false">3009611</guid>        </item>
        <item>
            <title>Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters</title>
            <link>http://www.medworm.com/index.php?rid=2990290&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F75l45n5x733j11l2%2F</link>
            <description>This study aimed to find out the expression features of VEGF and
 Cx43 and their significance in pancreatic cancer. The expression levels of VEGF and Cx43 protein in the samples, which came
 from 100 patients of human pancreatic cancer tissues and adjacent normal pancreatic tissues, were examined by using immunohistochemical
 streptavidin–peroxidase (S–P) method, Western-blotting, and RT–PCR analyses. Compared with adjacent normal pancreatic tissues,
 RT–PCR showed that the expression of VEGF mRNA was significantly higher in pancreatic cancer tissues (0.788&amp;nbsp;±&amp;nbsp;0.290, P&amp;nbsp;&amp;lt;&amp;nbsp;0.01) and Cx43 mRNA was significantly lower in pancreatic cancer tissues (0.403&amp;nbsp;±&amp;nbsp;0.204, P&amp;nbsp;&amp;lt;&amp;nbsp;0.01). The expression of VEGF protein was higher in pancreatic cancer tiss...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2990290</comments>
            <pubDate>Thu, 12 Nov 2009 09:10:14 +0100</pubDate>
            <guid isPermaLink="false">2990290</guid>        </item>
        <item>
            <title>Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells</title>
            <link>http://www.medworm.com/index.php?rid=2990291&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn0x44262570742k4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The medicinal properties of curcumin are well documented in Indian and Chinese systems of medicine, which refer to its wide
 use in the treatment of some diseases. It has shown to have anti-carcinogenic properties and is known to prevent tumor development
 in some cancers. In our study, we confirmed that the expression of miR-15a and miR-16 was upregulated and that of Bcl-2 was
 downregulated in curcumin-treated MCF-7 cells. Silencing miR-15a and miR-16 by specific inhibitors restored the expression
 of Bcl-2. Thus, we concluded that curcumin can reduce the expression of Bcl-2 by upregulating the expression of miR-15a and
 miR-16 in MCF-7 cells.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9344-3Authors
		Jie Yang, Tangdu Hospital Departm...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2990291</comments>
            <pubDate>Thu, 12 Nov 2009 09:10:03 +0100</pubDate>
            <guid isPermaLink="false">2990291</guid>        </item>
        <item>
            <title>Interleukin-1beta and tumor necrosis factor-alpha regulation of CDX2 homeobox gene through nuclear factor kappa B-dependent pathway in the intestinal-type gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=2990292&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6272654k1617850p%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aims of this study were to reveal the correlation between the transcription factor CDX2 and proinflammatory cytokines
 interleukin-1beta, tumor necrosis factor-alpha in the gastric cancerous tissues and gastric cancer cell line. Expression of
 CDX2 and proinflammatory cytokines in the gastric cancer tissues was analyzed by immunohistochemistry, immunoblotting and
 ELISA. The effect of interleukin-1beta and tumor necrosis factor-alpha on CDX2 messenger RNA, protein and promoter activity
 was analyzed in gastric cancer cell line AGS using real-time PCR, immunoblotting and EMSA. In the gastric cancerous tissues,
 CDX2 expression was found to exhibit an inverse correlation with the levels of interleukin-1beta (P&amp;nbsp;=&amp;nbsp;0.040) and tumor necrosis factor-alpha (P&amp;nbsp...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2990292</comments>
            <pubDate>Thu, 12 Nov 2009 09:09:52 +0100</pubDate>
            <guid isPermaLink="false">2990292</guid>        </item>
        <item>
            <title>Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center</title>
            <link>http://www.medworm.com/index.php?rid=2986144&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6160wh53517007j5%2F</link>
            <description>This study investigates the clinical, pathologic and prognostic
 characteristics of gastroenteropancreatic neuroendocrine tumors that presented to the Medical Oncology Outpatient Clinic,
 İstanbul University, Cerrahpaşa School of Medicine from 1995 to 2006 (n&amp;nbsp;=&amp;nbsp;86). The mean age of the patients was 52&amp;nbsp;±&amp;nbsp;14 and the male-to-female ratio was 0.87. The most common site of involvement
 was the stomach. Midgut intestinal tumors seemed to have significant female predominance compared to hindgut intestinal tumors
 (P&amp;nbsp;=&amp;nbsp;0.016). Most of the patients had metastatic disease with a prevalence of 34.9%. Poorly differentiated tumors and mixed
 neuroendocrine carcinomas were significantly larger than 2&amp;nbsp;cm (P&amp;nbsp;=&amp;nbsp;0.0001). The median survival was 139&amp;nbsp;months...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986144</comments>
            <pubDate>Wed, 11 Nov 2009 19:12:11 +0100</pubDate>
            <guid isPermaLink="false">2986144</guid>        </item>
        <item>
            <title>Pharmacogenetics and pharmacoepigenetics of gemcitabine</title>
            <link>http://www.medworm.com/index.php?rid=2982436&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7164r13w6561076j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Gemcitabine (2′,2′-difluoro 2′deoxycytidine, dFdC) is an analog of cytosine with distinctive pharmacological properties and
 a wide antitumor-activity spectrum. The pharmacological characteristics of gemcitabine are unique because two main classes
 of genes are essential for its antitumor effects: membrane transporter protein-coding genes, whose products are responsible
 for drug intracellular uptake, as well as enzyme-coding genes, which catalyze its activation and inactivation. The study of
 the pharmacogenetics and pharmacoepigenetics of these two gene classes is greatly required to optimize the drug’s therapeutic
 use in cancer. This review aims to provide an update of genetic and epigenetic bases that may account for interindividual
 variation in therapeuti...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2982436</comments>
            <pubDate>Tue, 10 Nov 2009 07:52:53 +0100</pubDate>
            <guid isPermaLink="false">2982436</guid>        </item>
        <item>
            <title>Large-cell neuroendocrine carcinoma of the ampulla of Vater</title>
            <link>http://www.medworm.com/index.php?rid=2974771&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw321213800n6wt83%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Large-cell neuroendocrine carcinoma is a high-grade neuroendocrine carcinoma, originally described in the lung. The tumor
 rarely occurs in extrapulmonary sites like the gastrointestinal tract, and only few examples have been described in the ampulla
 of Vater. A new case of large-cell neuroendocrine carcinoma of the ampulla of Vater in a 60-year-old man is reported. After
 pancreatoduodenectomy, macroscopic examination revealed ulcerated tumor in the region of the ampulla of Vater. Microscopically,
 the tumor exhibited organoid, predominantly nested growth pattern, consisting of large, polygonal cells with pleomorphic nuclei.
 Average number of mitoses was 36 per 10 high-power fields. Small and large areas of necrosis were identified. Immunohistochemically,
 the tumor ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2974771</comments>
            <pubDate>Sat, 07 Nov 2009 07:37:05 +0100</pubDate>
            <guid isPermaLink="false">2974771</guid>        </item>
        <item>
            <title>The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater</title>
            <link>http://www.medworm.com/index.php?rid=2974772&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd11u01711116x052%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Adenocarcinoma arising from the ampulla of Vater is a rare neoplasm that accounts for only 0.2% of all gastrointestinal tract
 malignancies and has limited data regarding its frontline therapy. We investigated the treatment outcomes in patients with
 advanced adenocarcinoma of the ampulla of Vater receiving frontline cisplatin-based combination chemotherapy. We analyzed
 29 patients with advanced adenocarcinoma of the ampulla of Vater who had been treated by frontline cisplatin-based combination
 chemotherapy between June 2003 and April 2008. The chemotherapeutic agent added to cisplatin was gemcitabine in 9 patients
 and fluorouracil (FU) in 20 patients (11; intravenous 5-FU and 9; oral 5-FU (capecitabine)). The median age of patients was
 56&amp;nbsp;years (range, 36–78...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2974772</comments>
            <pubDate>Sat, 07 Nov 2009 07:37:03 +0100</pubDate>
            <guid isPermaLink="false">2974772</guid>        </item>
        <item>
            <title>Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review</title>
            <link>http://www.medworm.com/index.php?rid=2968547&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj831742724q672w5%2F</link>
            <description>We report two cases of stage IV malignant melanoma arising in patients treated with azathioprine for myasthenia gravis. In
 both cases, the melanoma metastases regressed upon withdrawal of immunosuppression. One patient remains melanoma free at 10&amp;nbsp;years,
 and the second patient experienced an 18-month disease free period. There is one prior case report in the medical literature
 to support full immune reconstitution for treatment in advanced immunosuppression-related melanoma, and one case series suggesting
 that transplant patients developing melanoma may benefit from a switch to sirolimus. Virtually, no data exist for the medical
 management of early stage melanoma in the immunosuppressed patients. We review the limited preclinical data in support of
 immune reconstitution and the d...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2968547</comments>
            <pubDate>Thu, 05 Nov 2009 07:46:28 +0100</pubDate>
            <guid isPermaLink="false">2968547</guid>        </item>
        <item>
            <title>Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=2960349&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F087j74340r62t5x5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this paper was to identify novel proteins involved in the development of gastric cancer (GC). Isobaric tags for
 relative and absolute quantification (iTRAQ) analysis was adopted to separate the differentially expressed proteins between
 normal gastric epithelial cell line GES-1 and GC cell line SGC7901. Western blotting was utilized to validate the increased
 expression of sorcin in SGC7901; immunohistochemistry was performed to investigate its relationship with clinicopathological
 features of GC. Twelve differential proteins were identified. Seven proteins were found to be significantly upregulated (≥twofold),
 while five proteins were markedly downregulated (≤0.5-fold), in SGC7901 cells. Sorcin was detected by this proteomic approach
 with a 5.4-fold ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960349</comments>
            <pubDate>Tue, 03 Nov 2009 14:16:38 +0100</pubDate>
            <guid isPermaLink="false">2960349</guid>        </item>
        <item>
            <title>Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication</title>
            <link>http://www.medworm.com/index.php?rid=2960351&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff7503q682p656m2g%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to evaluate the efficacy and toxicity of docetaxel (TAX), cisplatin (CDDP), and fluorouracil (5-FU)
 plus leucovorin (CF) as the neoadjuvant chemotherapy (NACT) regimens in the treatment of nonresectable advanced gastric cancer.
 Twelve patients with nonresectable advanced gastric cancer were treated with NACT regimens consisted of docetaxel, cisplatin,
 fluorouracil, plus leucovorin before operation. Nine of the 12 patients were downstaged and 8 were radically operated after
 the end of the NACT. The overall response rate was 75% with 8.3% complete response and 66.7% partial response, and the ascites
 disappeared in 63.6%. The most common toxicities were bone marrow suppression, nausea, vomiting, alopecia, and heptoses. The
 toxicities were re...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960351</comments>
            <pubDate>Tue, 03 Nov 2009 14:16:36 +0100</pubDate>
            <guid isPermaLink="false">2960351</guid>        </item>
        <item>
            <title>Blood ABO groups and risk of breast cancer</title>
            <link>http://www.medworm.com/index.php?rid=2960350&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F74424r6j912408km%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s12032-009-9346-1Authors
		Didem S. Dede, Hacettepe University Institute of Oncology Department of Medical Oncology Sıhhiye 06100 Ankara TurkeySercan Aksoy, Hacettepe University Institute of Oncology Department of Medical Oncology Sıhhiye 06100 Ankara TurkeyOmer Dizdar, Hacettepe University Institute of Oncology Department of Medical Oncology Sıhhiye 06100 Ankara TurkeyPamir Cerci, Hacettepe University Institute of Oncology Department of Medical Oncology Sıhhiye 06100 Ankara TurkeyIbrahim Gullu, Hacettepe University Institute of Oncology Department of Medical Oncology Sıhhiye 06100 Ankara TurkeyYavuz Ozisik, Hacettepe University Institute of Oncology Department of Medical Oncology Sıhhiye 06100 Ankara TurkeyKadri ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960350</comments>
            <pubDate>Tue, 03 Nov 2009 14:16:36 +0100</pubDate>
            <guid isPermaLink="false">2960350</guid>        </item>
        <item>
            <title>Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion</title>
            <link>http://www.medworm.com/index.php?rid=2960353&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F630735n25705706j%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Presence of the Philadelphia chromosome in acute lymphoblastic leukemia is the single most adverse prognostic marker associated
 with high risk of disease relapse and poor prognosis. Allogeneic haematopoietic stem cell transplantation is considered as
 the only curative option in adults with Philadelphia-positive acute lymphoblastic leukemia, but relapse remains the main cause
 of treatment failure. Moreover, long-term survival rates are markedly decreased when transplanted patients are not in complete
 remission. Incorporation of tyrosine kinase inhibitors into transplantation strategy in patients with Philadelphia-positive
 acute lymphoblastic leukemia may improve prognosis of the disease. Imatinib combined with conventional chemotherapy and used
 in conjunction with ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960353</comments>
            <pubDate>Tue, 03 Nov 2009 14:16:35 +0100</pubDate>
            <guid isPermaLink="false">2960353</guid>        </item>
        <item>
            <title>Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer</title>
            <link>http://www.medworm.com/index.php?rid=2960352&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6h6464u46pu52634%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of this study was to determine outcome of the ratio of metastatic lymph nodes to the total number of dissected
 lymph nodes (MLR) in patients with gastric cancer. We retrospectively analyzed 111 patients who underwent D2 lymph node dissection. The prognostic factors including UICC/AJCC TNM classification and MLR were evaluated by univariate
 and multivariate analysis. The MLR was significantly higher in patients with a larger tumor, lymphatic vessel invasion, blood
 vessel invasion and perineural invasion, and advanced stage. Moreover, the MLR was significantly associated with the depth
 of invasion and the number of lymph node metastasis. The univariate analysis revealed for overall survival (OS) that stage
 of disease, lymphatic vessel invasion, blood vess...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2960352</comments>
            <pubDate>Tue, 03 Nov 2009 14:16:35 +0100</pubDate>
            <guid isPermaLink="false">2960352</guid>        </item>
        <item>
            <title>Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials</title>
            <link>http://www.medworm.com/index.php?rid=2947853&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr2754k570w485286%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Antifungal prophylaxis using fluconazole or itraconazole has been studied for many years but still no consensus has been reached
 regarding their safety and effectiveness. We performed a systematic meta-analysis to assess the efficacy of fluconazole compared
 to itraconazole in neutropenic patients with hematological malignancies. We gathered the data for our analysis from MEDLINE,
 EMBASE, Cochrane-controlled trials register, Cochrane Library, and Science Citation Index (1/1990 to 1/2009) searches. Risk
 ratio (RR) and 95% confidence intervals (CIs) were calculated using the random effect model. Nine RCTs were identified that
 were published in full text. Significantly, fewer patients were withdrawn from the studies due to the development of adverse
 effects with fluco...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947853</comments>
            <pubDate>Fri, 30 Oct 2009 07:41:24 +0100</pubDate>
            <guid isPermaLink="false">2947853</guid>        </item>
        <item>
            <title>Over-expression of Na+/H+ exchanger 1 and its clinicopathologic significance in hepatocellular carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=2947852&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa22m85432p33jhj0%2F</link>
            <description>In this study, we first analyzed the NHE1 expression in 100 cases of hepatocellular carcinoma (HCC) and found that NHE1, at
 both messenger RNA and protein levels, was over-expressed in majority of HCC tissues compared with matched non-cancerous tissue.
 In addition, the increased expression of NHE1 correlated with tumor size, venous invasion and advanced pTNM stage (P&amp;nbsp;&amp;lt;&amp;nbsp;0.05). Kaplan–Meier curves demonstrated that patients with increased NHE1 expression were at significantly increased risk
 for shortened survival time (P&amp;nbsp;&amp;lt;&amp;nbsp;0.05). This is the first demonstration that the expression level of NHE1 is correlated with tumor progression and prognosis
 in HCC. We proposed that NHE1 may have diagnostic and therapeutic potential for patients with HCC.
 
	Content Type Jo...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947852</comments>
            <pubDate>Fri, 30 Oct 2009 07:41:24 +0100</pubDate>
            <guid isPermaLink="false">2947852</guid>        </item>
        <item>
            <title>Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?</title>
            <link>http://www.medworm.com/index.php?rid=2947851&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Frhh3mj7j136566rp%2F</link>
            <description>Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s12032-009-9322-9Authors
		Ali Alkan, Hacettepe University School of Medicine Department of Internal Medicine Ankara TurkeyUgur Sahin, Hacettepe University School of Medicine Department of Internal Medicine Ankara TurkeyKadri Altundag, Hacettepe University Institute of Oncology Department of Medical Oncology 06100 Sihhiye, Ankara Turkey
	

	
		Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560 (Source: Medical Oncology)</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2947851</comments>
            <pubDate>Fri, 30 Oct 2009 07:41:24 +0100</pubDate>
            <guid isPermaLink="false">2947851</guid>        </item>
        <item>
            <title>MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=2936164&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg1k77615g6100400%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of the study was to evaluate the influence of the MDR1 C3435T polymorphism on the therapeutic response in 23 patients treated with cetuximab plus irinotecan for irinotecan refractory
 liver metastatic colorectal cancer considering their KRAS status. Indeed, irinotecan and its active metabolite (SN-38) are both substrates of P-glycoprotein (P-gp) encoded by MDR1. Patients received cetuximab and irinotecan up to progression. The overall survival was 55% at 10&amp;nbsp;months. Overall, four patients
 had an undetermined KRAS status and two patients with mutated KRAS were in progression disease. The response to treatment was observed after 3&amp;nbsp;months among the 17 wild-type KRAS patients. Two patients presented a progressive disease (1 TT and 1 CT), eight patients had...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2936164</comments>
            <pubDate>Tue, 27 Oct 2009 18:07:10 +0100</pubDate>
            <guid isPermaLink="false">2936164</guid>        </item>
        <item>
            <title>Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes</title>
            <link>http://www.medworm.com/index.php?rid=2936165&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg46j1562v20p31v2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;An extremely rare case of primary small cell carcinoma of the pleura with an emphasis on KIT and platelet-derived growth factor receptor-α (PDGFRA) genes is reported here. A 67-year-old man underwent left testicular orchiectomy because of a testicular tumor. The tumor
 was immunohistochemically shown to be diffuse large B-cell lymphoma. The patient was treated with chemotherapy and radiation
 and followed up in our hospital. Eight years after the orchiectomy, the patient (75&amp;nbsp;years old) developed left pleural tumor
 and pleural effusion, and a biopsy was performed. The biopsy revealed a medullary malignant tumor consisting of small round
 and spindle cells. The following three possibilities were considered: recurrent lymphoma, mesothelioma, and small cell carcinoma...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2936165</comments>
            <pubDate>Tue, 27 Oct 2009 09:05:58 +0100</pubDate>
            <guid isPermaLink="false">2936165</guid>        </item>
        <item>
            <title>Cell cycle inhibition and apoptosis induced by curcumin in Ewing sarcoma cell line SK-NEP-1</title>
            <link>http://www.medworm.com/index.php?rid=2936166&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy511106m48m22505%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Curcumin is a naturally occurring polyphenolic compound found in the turmeric, which is used as food additive in Indian cooking
 and as a therapeutic agent in traditional Indian medicine. Curcumin is currently under investigation as a chemotherapeutic
 and chemopreventive agent in adult cancer models at both pre-clinical and clinical levels. In this preliminary study, we show
 that curcumin is effective in causing cell cycle arrest, inducing apoptosis, and suppressing colony formation in the Ewing
 sarcoma cell line SK-NEP-1. Curcumin causes upregulation of cleaved caspase 3 and downregulation of phospho-Akt, producing
 apoptosis in Ewing sarcoma cells at an inhibitory concentration 50% (IC50) of approximately 4&amp;nbsp;μM. Our findings indicate a
 need for further evalua...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2936166</comments>
            <pubDate>Tue, 27 Oct 2009 09:05:57 +0100</pubDate>
            <guid isPermaLink="false">2936166</guid>        </item>
        <item>
            <title>Clinicopathological analysis of primary epithelial appendiceal neoplasms</title>
            <link>http://www.medworm.com/index.php?rid=2924204&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F088538405r124335%2F</link>
            <description>The objective of this study was to evaluate the clinicopathologic presentation
 and outcome of patients with appendiceal tumors treated at our institution over a 15-year period. We identified patients with
 appendiceal tumors diagnosed or treated at our institution from January 1989 through May 2004. Chart review for age, gender,
 signs and symptoms at diagnosis, and treatment was performed. Review of the pathologic specimens was performed and tumors
 were classified as DPAM, PMCA I/D, or PMCA. Forty patients were identified (median age 52.5&amp;nbsp;years; males 38%). The number
 of patients with DPAM, PMCA I/D, and PMCA was 15 (38%), 6 (15%), and 18 (46%), respectively. Peritoneal involvement was seen
 in 11 (73%) of patients with DPAM, 5 (83%) of PMCA I/D, and 11 (61%) of PMCA. The median s...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2924204</comments>
            <pubDate>Thu, 22 Oct 2009 18:41:18 +0100</pubDate>
            <guid isPermaLink="false">2924204</guid>        </item>
        <item>
            <title>Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion</title>
            <link>http://www.medworm.com/index.php?rid=2921363&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu5m1m3p58h176j4u%2F</link>
            <description>We present a case of seizures after intrathecal administration
 of methotrexate, during the management of diffuse large B-cell lymphoma. There was complete resolution of the CNS lesions
 after chemotherapy along with the interval development of diffuse cerebral edema. We hypothesize that tumor lysis is the underlying
 mechanism of this untoward event, resulting in the corresponding clinical presentation.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9338-1Authors
		Lohith S. Bachegowda, Hahnemann University Hospital/Drexel University College of Medicine Department of Internal Medicine Philadelphia PA 19102 USAPetros D. Grivas, Hahnemann University Hospital/Drexel University College of Medicine Department of Internal Medicine Philadelphia PA 19102 USARachna An...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2921363</comments>
            <pubDate>Thu, 22 Oct 2009 06:09:55 +0100</pubDate>
            <guid isPermaLink="false">2921363</guid>        </item>
        <item>
            <title>The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment</title>
            <link>http://www.medworm.com/index.php?rid=2921364&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb6696307443454l1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We aimed to investigate the prognostic significance of neutrophil, lymphocyte, platelet, mean platelet value (MPV), platelet-lymphocyte
 ratio (PLR) and neutrophil–lymphocyte ratio (NLR) in patients with locally advanced gastric cancer (LAGC). One hundred sixty-eight
 patients with LAGC who had been followed-up between 2004 and 2008 were included in present study. The results of hematological
 (platelet, lymphocyte, neutrophil and MPV) and biochemical (uric acid and LDH) parameters were evaluated before treatment.
 NLR was divided into two groups as &amp;lt;2.56 and ≥2.57 and PLR was also divided into two groups as ≤160 and &amp;gt;160. Platelet counts
 and lymphocyte counts were also divided into two groups; ≤300.000/mm3 and &amp;gt;300.000/mm3, and &amp;lt;1,500/mm3 and ≥1,...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2921364</comments>
            <pubDate>Thu, 22 Oct 2009 06:09:53 +0100</pubDate>
            <guid isPermaLink="false">2921364</guid>        </item>
        <item>
            <title>Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report</title>
            <link>http://www.medworm.com/index.php?rid=2921365&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj1512q84p1424856%2F</link>
            <description>We report a 47-year-old patient with localised
 breast cancer who developed thrombotic microangiopathy (HUS/TTP) acutely following concurrent neoadjuvant therapy with trastuzumab
 and docetaxel. We demonstrate from our case that mild confusion occurring on a background of mild anaemia and thrombocytopenia
 may sometimes be the only clue to the diagnosis. Clinicians should be aware of the possibility of thrombotic microangiopathy
 associated with trastuzumab and docetaxel therapy, as early intervention can improve clinical outcome.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9333-6Authors
		Keith Siau, Great Western Hospital Department of Medicine SN3 6BB Swindon UKMohini Varughese, Musgrove Park Hospital Department of Oncology TA1 5DA Taunton UK
	

	
		Jour...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2921365</comments>
            <pubDate>Thu, 22 Oct 2009 06:09:52 +0100</pubDate>
            <guid isPermaLink="false">2921365</guid>        </item>
        <item>
            <title>Tamoxifen and arrhythmia</title>
            <link>http://www.medworm.com/index.php?rid=2917502&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft285575275h13345%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Tamoxifen is an orally active selective estrogen receptor modulator that is used in the treatment of breast cancer and is
 currently the world’s largest selling drug for that purpose. However, it has some side effects including hot flashes, menstrual
 irregularity, vaginal discharges, uterine bleeding, uterine endometrial cancer, hypercoagulability, steatosis hepatis, risk
 of trombembolism. Long-term data from clinical trials have failed to demonstrate a cardioprotective effect and beneficial
 effects on serum lipid profiles. Arrhythmia secondary to tamoxifen is very rare.
 
	Content Type Journal ArticleCategory Letter to the editorDOI 10.1007/s12032-009-9334-5Authors
		Ladislav Slovacek, Charles University Hospital Faculty of Medicine, Department of Clinical Oncolog...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2917502</comments>
            <pubDate>Wed, 21 Oct 2009 12:12:28 +0100</pubDate>
            <guid isPermaLink="false">2917502</guid>        </item>
        <item>
            <title>Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine</title>
            <link>http://www.medworm.com/index.php?rid=2905933&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbur34v4173566363%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Functional polymorphisms in the thiopurine methyl transferase (TPMT) gene have been associated with varying levels of enzyme
 activity and the occurrence of toxicity related to thiopurines. A total of 98 patients (66 pediatric and 32 adults) with precursor
 B acute lymphoblastic leukemia (Pre-B ALL) were evaluated for TPMT gene polymorphisms. The inability to tolerate 6-mercaptopurine
 (6-MP) at conventional doses was considered as a surrogate marker of hematologic toxicity. The allele frequency of TPMT*2,
 *3A, *3B and *3C in the study population was 0.5, 0, 0 and 2.6%, respectively, similar to the frequency observed in other
 Asian populations. Five patients were heterozygous for TPMT*3C variant allele, and one of these patient’s was compound heterozygous
 with TPMT...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905933</comments>
            <pubDate>Thu, 15 Oct 2009 06:28:58 +0100</pubDate>
            <guid isPermaLink="false">2905933</guid>        </item>
        <item>
            <title>Infections in acute myeloid leukemia: an analysis of 382 febrile episodes</title>
            <link>http://www.medworm.com/index.php?rid=2905932&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk7881622mv388124%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Neutropenic fever is an important cause of morbidity and mortality during therapy of acute myeloid leukemia (AML). We retrospectively
 analyzed 382 febrile episodes encountered during induction and consolidation chemotherapy to determine the potential etiology,
 microbiologic spectrum, response/resistance to antibiotics and outcome. Between May, 2001 and December, 2006, 95 patients
 with de novo non-M3 AML received remission induction chemotherapy followed by consolidation in those who achieved complete
 remission. Patients median age was 28&amp;nbsp;years, ranging from 2 to 61&amp;nbsp;years, 26 patients were ≤15&amp;nbsp;years of age. There were 57
 males and 38 females. Febrile neutropenia was defined as per international guidelines. A total of 382 febrile episodes were
 recor...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905932</comments>
            <pubDate>Thu, 15 Oct 2009 06:28:58 +0100</pubDate>
            <guid isPermaLink="false">2905932</guid>        </item>
        <item>
            <title>Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=2905931&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F43430570g1461766%2F</link>
            <description>We report
 a case of paraneoplastic hypercalcemia, resistant to conventional treatment but recovers by sunitinib treatment as the first
 case in the literature, in a 33-years-old man with metastatic RCC. At the sixth month of follow-up period, in this case, serum
 calcium level was still in normal ranges. Besides sunitinib is effective in symptom control, it is also helpful in management
 of paraneoplastic hypercalcemia, a life-threatening entity.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s12032-009-9327-4Authors
		Halit Karaca, Erciyes University Medical Faculty Departments of Medical Oncology Kayseri TurkeyAyhan Lale, Erciyes University Medical Faculty Departments of Internal Medicine Kayseri TurkeyMustafa Dikilitas, Erciyes University Medical Faculty Departments ...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905931</comments>
            <pubDate>Thu, 15 Oct 2009 06:28:58 +0100</pubDate>
            <guid isPermaLink="false">2905931</guid>        </item>
        <item>
            <title>Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib</title>
            <link>http://www.medworm.com/index.php?rid=2905934&amp;cid=s_35998_6_f&amp;fid=35998&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F328138j20326uk68%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Serum concentrations of tissue polypeptide-specific antigen (TPS) and Cytokeratin-19-Fragments (CYFRA 21-1) before operation
 or chemotherapy have been proved to be a useful prognostic tool for patients with NSCLC, but the related data for advanced
 NSCLC patients treated with gefitinib are limited. We retrospectively reviewed 122 advanced NSCLC patients treated with gefitinib
 between April 2002 and August 2007. Multiple clinical factors including pretreatment serum levels of TPS and CYFRA 21-1, age,
 gender, performance status (PS), smoking history, stage, histology, the number of prior chemotherapy and the patients’ clinical
 outcomes were analyzed. Patients without elevated serum TPS levels had a more RR (36.8%) than those with elevated serum TPS
 levels (18.5%) (...</description>
            <author>Medical Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2905934</comments>
            <pubDate>Thu, 15 Oct 2009 06:28:57 +0100</pubDate>
            <guid isPermaLink="false">2905934</guid>        </item>
    </channel>
</rss>
